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ABSTRACT OF THE DISSERTATION 
Tumors Interrupt IRF8-Mediated Dendritic Cell Development to  
Overcome Immune Surveillance 
by 
Melissa A. Meyer 
Doctor of Philosophy in Biology and Biomedical Sciences 
Molecular Cell Biology 
Washington University in St. Louis, 2018 
Professor David G. DeNardo 
 
Tumors employ multiple mechanisms to evade immune surveillance. One mechanism is 
tumor-induced myelopoiesis, which expands immune suppressive granulocytes and 
monocytes to create a protective tumor niche shielding even antigenic tumors. As 
myeloid cells and immune-stimulatory conventional dendritic cells (cDCs) are derived 
from the same progenitors, it is logical that tumor-induced myelopoiesis might also 
impact cDC development. The cDC subset cDC1 is marked by CD141 in humans and 
CD103 or CD8α in mice. cDC1s act by cross presenting antigen and activating CD8+ T 
cells. Given these functions, CD103+ cDC1s can support anti-tumor CD8+ T cell 
responses. However, CD103+ cDC1 numbers are limited within the tumor 
microenvironment. To understand how CD103+ cDC1s are restricted in the tumor, we 
investigated their development in the bone marrow (BM). We found that the presence of 
localized primary tumors resulted in systemic decreases in CD141+ cDC1s in breast and 
pancreatic cancer patients and animal models. Mechanistically, tumor cell-produced 
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granulocyte stimulating factor (GCSF) mediates the downregulation of the transcription 
factor interferon regulatory factor 8 (IRF8) in BM progenitors, leading to reduced cellular 
potential for cDC1 development. Tumor-induced reductions in cDC1-development 
suppressed the ability of the host to mount anti-tumor CD8+ T cell responses and 
control tumor growth. Further, BM and systemic decreases in CD141+ cDC1s and their 
progenitors correlate with patient outcome. Neutralizing GCSF restored cDC1 
differentiation and recovered responsiveness to cDC-mediated immunotherapy. These 
data suggest a new mechanism of immune-escape whereby tumors downregulate 
cDC1 differentiation from BM progenitors to impair anti-tumor immunity.
 1 
Chapter 1: Introduction 
Tumors do not develop autonomously, but rather in the context of a complex 
microenvironment. In addition to tumor cells, solid tumor tissues contain a multitude of 
cell types and structural proteins that construct the tumor organ. It has long been 
appreciated that a component of the tumor microenvironment is the immune response. 
The immune system and the tumor dynamically interact ultimately leading to tumor 
control or tumor progression.   
 The goal of this thesis is to describe one way in which the tumor subverts the 
immune system leading to tumor progression. First, I will describe a tumor-induced 
defect in dendritic cell differentiation in both mice and patients. Second, I will describe 
how tumor-derived GCSF inhibits IRF8 expression reducing dendritic cell differentiation. 
Finally, I will discuss the implications this has on anti-tumor CD8+ T cell responses and 
immuno-therapeutic strategies. 
The Immune System and Cancer 
 Over 100 years of understanding have led to the current models we have of 
cancer-immune interactions. Observations by William Coley dating back to the 1890s 
suggested bacteria infections in patients could lead to spontaneous tumor regression. 
Coley, and others, proceeded to inject their patients’ tumors with streptococcus cultures 
with the intent of directing tumor regression. Pending the true induction of erysipelas 
including severe fever, chills and vomiting, many of these patients incurred a true 
remission, some lasting many years1. Coley speculates that toxins from the bacteria 
were inducing some type of systemic stimuli. We now understand that the bacteria 
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Coley injected into the tumors was initiating a productive inflammatory response thereby 
calling the attention of the immune system to the tumor that was present at the site of 
bacterial infection2. In 1907, Paul Ehrlich was the first to propose that tumor 
development was suppressed by immune responses3. This is likely why we can endure 
the development of neoplastic cells each day from mutagens, such as UV light from the 
sun, without frequently developing frank cancerous lesions. This process was later 
termed tumor immunosurveillance, describing how the immune system patrols for 
transformed cells and, when it is able to recognize those cells, destroys them4.  This is 
further demonstrated by the increased incidence of cancer in immune deficient patients, 
those with HIV/AIDS and those undergoing immune suppression for organ transplant5,6. 
Though the immune response has strong anti-tumor potential, the dynamic 
interaction between the tumor and the immune system can reshape the immune 
response to be tumor promoting. It was also hypothesized long ago by Virchow that 
chronic inflammation was a driver of tumor progression. He showed that chronic 
inflammation caused by irritation plus tissue injury led to aberrant cell proliferation7. We 
now understand that chronic inflammation induces a wound-healing program that 
supports tissue growth and remodeling while suppressing targeted adaptive immune 
responses that could lead to tissue injury. This is an ideal environment for tumors to 
grow, leading Dvorak to describe tumors as “the wound which never heals”8. Chronic 
inflammatory conditions are known as risk factors for tumor development. This includes 
conditions such as pancreatitis, Crohn’s disease and hepatitis9. Environmental irritants 
can also induce cancer-causing chronic inflammation. For example, smoking can 
promote lung cancer by not only inducing mutations but also by causing chronic 
 
 
3 
irritation and inflammation10. Together these historical and clinical observations show 
cancer progression is in balance with the immune system, and that each can shape the 
other.  
Adaptive and Innate Immune Responses in Solid Tumors 
Diverse populations of the immune cells within the tumor interact with tumor 
cells, and also each other, to shape the immune response against the tumor. Here, I will 
focus on the interaction between the T cells of the adaptive immune system, the 
myeloid cells of the innate immune system and dendritic cells (DCs) that bridge 
between the two compartments.  
Antigen Presentation and T Cell Activation 
 T cells are a major effector population of the adaptive immune response with 
specific and highly regulated functions. T cells are programmed to respond to specific 
antigen, pieces of information that can be derived from foreign or harmful pathogens. 
Mutational changes or aberrant expression of normal proteins during cancer provide 
antigens for the immune system to “work on”11,12. In fact, mutational load corresponds 
with response to T cell stimulatory therapies in some tumor types13,14. In order to 
become activated from a naïve state, T cell must experience a specific antigen 
presented on an antigen presenting cells in context of major histocompatibility complex 
(MHC) through its T cell receptor (TCR). After binding of the TCR to MHC, the T cell 
must receive co-stimulation primarily through its CD28 receptor. This signal can be 
further amplified by additional co-stimulatory pairings, such as CD40-CD40L and OX40-
OX40L. Finally, during this process, specifically CD4+ T cell will receive cytokine signals 
that will determine their subset and function. CD8+ T cells activation most often requires 
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“help” from activated CD4+ T cells. CD4+ T cells act by further activating the antigen-
presenting cell to up-regulatory co-stimulatory molecules and cytokine expression, by 
providing co-stimulatory receptors and by producing IL-2, a growth factor that supports 
T cell expansion. These signals in total tell the T cell to survive and proliferate (Fig. 
1.1a). Once activated, CD8+ T cells can engage in cytotoxic activity against any target 
cell, including tumor cells, that is presenting its designated antigen on MHCI15. Antigen 
can be presented on many different cells, but different populations vary in their ability to 
activate and shape the T cell response. DCs are professional antigen presenting cells. 
They have increased expression of co-stimulatory molecules and can engage in cross 
presentation, a process by which antigen is taken up from outside the cell and 
presented in a context that is likely to lead to T cell activation15,16.  
 T cell activation is often disrupted in tumor tissues. First, tumors can induce 
dysfunction in DCs. DCs require maturation signals, like toll-like receptor or NOD-like 
receptor signaling, that allow sensing of microbial products and tissue damage17,18.  In 
the context of cancer, this requires immunologic cell death, like death by necrosis, 
instead of a tolerogenic cell death, like apoptosis. When these signals are received by 
DCs, antigen-presenting machinery, co-stimulatory molecules and cytokines are 
upregulated to support T cell activation17,18. The tumor microenvironment does not 
necessarily produce these signals or may counteract them by overproducing 
suppressive cytokines such as IL-1018,19. For these reasons, DC are usually immature 
within the tumor microenvironment and do not function well in antigen presentation. 
Immature DCs are also poor at traversing from the tumor to the lymph node where 
antigen presentation can occur more efficiently to stimulate naïve T cells20-25. This also 
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alludes to the fact that the tumor tissue itself is often not a good place for mature DCs to 
present antigen. Tumors can be loaded with CD4+ T cells that have immune 
suppressive functions, like CD4+ T regulatory cells and Th2 CD4+ T cells. Antigen 
presentation to CD8+ T cells in this context will lead to anergy due to reduced DC co-
stimulatory receptor expression and reduced IL-2 availability26-28. Finally, DCs are rare 
within the tumor microenvironment and are competing for tumor cell antigen with other 
myeloid cells. This means antigen may not be preferentially taken up by DCs and 
instead it may be take up by myeloid cells less apt to present to and activating T cells, 
supporting an anti-tumor CD8+ T cell response29,30.  
 T cells are further subdued in the tumor by immune checkpoints. Checkpoint 
receptors are expressed on T cells for the purpose of maintaining self-tolerance, 
preventing excessive tissue damage during infection, and preventing autoimmune 
disease. In cancer, these pathways are misused and dysregulated31. CTLA-4 and PD1 
are the T cell checkpoints that were first identified to be relevant in cancer, and work on 
these receptors has led clinically relevant therapies32. CTLA-4 competes with CD28 for 
binding to co-stimulatory molecules B7-1 and B7-2, and so it acts during T cell 
stimulation33-37. CTLA-4 can also be highly expressed on CD4+ T regulatory cells and 
controls their immune suppressive function38,39. PD1 is upregulated on T cells once they 
become activated and its ligands, PDL1 and PDL2, are expressed in the periphery32. 
PDL1 is often expressed on tumor cells as well as immune cells, and can be regulated 
by interferon gamma (IFNγ), a cytokine released by activated T cells40. PDL2 is 
primarily expressed on antigen presenting cells like macrophage and DCs and is also 
upregulated in response to cytokine signals derived from active T cell responses. 
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Ligation of PD1 sends an inhibitory signal and leads to reduced T cell function and 
survival41,42. In this way, PD1 signaling is the brakes on an active T cell responses. In 
sum, T cell activation is highly regulated and these mechanisms are hijacked by tumors 
to evade adaptive immune responses (Fig. 1.1b).   
Myeloid Cells in the Tumor Environment 
Myeloid infiltration is a common hallmark of solid tumors. Solid tumors send out 
recruitment factors that lead to the production and influx of granulocytes and monocytes 
to support tumor progression43.  
Granulocytes are generally known to be pro-inflammatory and short lived.  They 
can control pathogen through phagocytosis, pro-inflammatory degranulation and 
excretion of neutrophil extracellular traps (NETs), complexes of DNA and enzymes used 
to capture pathogens. Under wound healing conditions, granulocytes can contribute to 
tissue debridement and produce matrix remodeling enzymes and pro-angiogenic factors 
to support tissue repair44. During cancer, granulocytes are expanded through cytokine 
signaling such as tumor-induced granulocyte colony stimulating factor (GCSF) and 
granulocyte-macrophage colony stimulating factor (GMCSF). Other tumor-derived 
factors, most of which are Cxcr2 ligands, lead to pre-mature release of immature 
granulocytes from the bone marrow (BM) and recruitment into the tumor site45-48. A 
portion these populations recruited to the tumor site can be referred to as granulocytic 
myeloid derived suppressors cells (G-MDSCs). This population has been shown to be a 
precursor of mature granulocytes through in vitro differentiation assay, and so, I will 
refer to them at immature granulocytes45. In this state they have pro-tumor functions, 
including matrix remodeling and the release of angiogenic factors, like the functions 
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they exercise in wound healing, as well as immune suppressive functions against CD8+ 
T cells47.  
Monocytes are generally responsible for patrolling tissues, sensing inflammation 
and clearing waste18,49. Under inflammatory conditions, the monocytes are expanded in 
the BM and are recruited to sites of inflammation43. Like granulocytes, inflammatory 
monocytes are recruited to the tumor by factors like Ccl250. Also like granulocyte, 
monocytes can be suppressive to CD8+ T cell responses43,51. Once in the tumor site, 
inflammatory monocytes can contribute to the expanding pool of macrophages within 
the tumor tissue52. Though macrophages can have a multitude of roles within tissues, 
they are typically polarized by the cytokine milieu within the tumor site to be tumor 
promoting53. Macrophages can antagonize T cell responses by acting as poor antigen 
presenters, producing high levels of IL-10 to interrupt DC functions and polarizing the 
CD4+ T cell response towards a Th2 phenotype to suppress the CD8+ T cell 
response19,27,29. Further, macrophages can expression checkpoint molecules to inhibit 
productive T cell responses54. Our lab and others have also recently described a 
population of tissue resident macrophages that expands through in situ proliferation 
during cancer and are tumor promoting. These macrophages have been characterized 
to have a low antigen presenting characteristics and high wound healing characteristics, 
including production of ECM proteins54-56.   
 Myeloid cells can also enhance the metastatic process. Excessive granulocytes 
contribute to systemic immune suppression of anti-tumor CD8+ T cell responses, 
protecting circulating cancer cells from immune surveillance46. Further, NETs extruded 
by granulocytes can encapsulate metastatic tumor cells and hide them from cytolytic 
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immune cells57. Myeloid populations also seed pre-metastatic locations and can support 
metastasis by providing adhesion for circulating tumor cells, releasing matrix remodeling 
proteins to support invasion and inhibiting cytolytic immune responses58.   
 To subvert the immune response, tumors work to shift the balance from a CD8+ T 
cell-mediated adaptive immune response to one that predominated by suppressive 
myeloid cells and diminished in T cell function. 
Myeloid Differentiation in Health and Disease 
 Myeloid cells derive from progenitors found in the BM. The granulocyte, 
monocyte and DC lineage is seeded at the granulocyte-macrophage progenitor 
(GMP)59. From there, cells either differentiate into granulocyte precursors or 
macrophage-dendritic cell progenitors (MDP) that maintains monocyte and DC 
potential60,61. MDPs can then differentiate into monocytes or continue down the DC 
lineage. Monocytes can further differentiate into macrophages once they reach 
peripheral tissues52. Myeloid differentiation maintains a balance during homeostasis that 
is disrupted during disease (Fig. 1.2).  
 Myelopoiesis occurs when the body experiences inflammatory or stress stimuli. 
Under this process immature granulocytic and monocytic are expanded from 
progenitors in the BM and recruited to inflammatory sites43. With acute stimulation, this 
process resolves to prevent tissue damage. Under chronic stimulation, such as under 
chronic inflammation or cancer, the stimulatory signal persists and the expansion of the 
myeloid products is sustained62. Rather than the relatively fast differentiation into a 
mature state that leads to a robust anti-pathogen response seen in acute situations, the 
myeloid cells produced during chronic inflammation and cancer have a suppressive and 
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pro-growth phenotype usually associated with an immature state (Fig. 1.2)43 62. This is 
likely evolutionarily selected to prevent tissue damage and support wound healing62. 
This response is beneficial to cancer as “the wound which never heals”8.  Myelopoiesis 
during cancer leads to an accumulation of immature granulocytes and monocytes within 
the tumor and other systemic tissues. Even outside the primary tumor, these 
populations can have pro-tumorigenic and immune suppressive functions. In fact, the 
presence of an aggressive primary tumor can affect the outgrowth of a less aggressive 
secondary tumor, suggesting systemic changes may prime pre-metastatic site for tumor 
growth63.  
 Immune stimulatory DCs develop from the same progenitors as the expanding 
populations of immature granulocytes and monocytes. This led us to ask whether 
myelopoiesis was detrimental to DC development.  
Dendritic Cell Differentiation and cDC1 Function 
 DCs are the bridge between the innate and the adaptive immune system. Similar 
to the way macrophages and monocytes scavenge debris, DCs are able to engulf 
antigen, but instead use that antigen to promote a productive T cell response. In this 
section, I will discuss how DCs develop and the function of a specific subset, the 
cDC1s.  
Dendritic Cell Differentiation 
 DCs derive from the myeloid lineage. Like monocytes and macrophages, DCs 
differentiate from the GMP and MDP. From the MDP, cells differentiate into monocyte 
precursors or common dendritic cell progenitors (CDPs). CDPs can give rise to 
plasmacytoid DCs (pDCs) and the common DC (cDC) lineage64-66. When activated, 
 
 
10 
pDCs function by producing a high level of type 1 interferon and support anti-viral 
responses67,68. Moving towards the cDC lineage, CDPs differentiate into pre-DCs. Pre-
DCs can then traffic into the periphery before they differentiate into cDC1s or cDC2s17. 
cDC1s are marked by CD141 in humans and encompass both migratory CD103+ 
cDC1s and lymphoid-resident CD8α+ cDC1s in mice. cDC1s are potent in activating 
CD8+ T cells69-73. cDC2s are marked by CD1c in humans and encompass both 
migratory CD11b+Sirpα+ cDC2s and lymphoid-resident CD11b+Sirpα+CD4+ cDC2s69,72.  
DC differentiation in the BM is primarily driven by the cytokine fms-like tyrosine kinase 3 
ligand (Flt3L) and further DC maturation can be supported by granulocyte-macrophage 
colony stimulating factor (GM-CSF) in the periphery74-76. cDCs do not have a tissue 
resident component and turn over at a high rate, so DC differentiation in the BM is 
important to support systemic cDC numbers77,78.  
Recent RNA-seq and lineage tracing studies have shown that myeloid 
progenitors have a high degree of diversity in gene expression and likely commit to 
specific subsets and lineages earlier than is described in the distinct cellular lineage79,80.  
Similar studies have also identified pre-DCs that are committed to the cDC1 or cDC2 
lineage81-84. This can occur before pre-DCs traffic into the periphery, suggesting 
myeloid, and further DC, phenotype is determined at the point of development in the 
BM. This led us to ask how tumors were affecting DC differentiation in the BM, beyond 
what is known about regulation of DC maturation in the periphery. 
cDC1s-Shapers of the anti-Tumor CD8+ T-Cell Response 
 cDC1s are specialized in activating CD8+ T cells and, through this function, 
support anti-tumor adaptive immune responses. cDC1 development is driven by the 
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transcription factors interferon regulatory factor 8 (IRF8), basic leucine zipper 
transcription factor ATF-like 3 (Batf3), and inhibitor of DNA binding 2 (Id2)71,77,85,86. 
Unlike cDC1s, cDC2 down-regulate IRF8 and up-regulated IRF4 to support 
differentiation87. cDC1s can cross present antigen to activate CD8+ T cell responses. 
This process can happen in the periphery to re-activate CD8+ T cell responses but 
cDC1s also work to shuttle antigen from the periphery into the lymph node were naïve 
T-cells can be activated20,81,85,88,8990. In contrast, cDC2s stimulate CD4+ T cells, 
especially CD4+ T cells with a more tolerogenic phenotype73. Further, cDC1s are known 
to secrete factors that recruit CD8 T cells into tissues including Cxcl9/1091,92.  Finally, 
memory T cell responses are deficient in mice depleted of cDC1s90,91. Given these 
functions, it understandable that cDC1s have been implicated in initiation and 
maintenance of CD8+ T cell responses against tumors. CD103+ cDC1s are required to 
restrain tumor growth and support response to CD8+ T cell-mediated chemo- and 
immune-therapies in multiple mouse models of solid tumors. In patients, intratumoral 
CD141+ cDC1s numbers correlate with better outcomes in many types of solid tumors, 
including breast cancer19,29,30,81,85,92,93. Thus, cDC1s are important mediators of the anti-
tumor CD8+ T cell response and can function to control tumor progression in mice and 
humans.  
Unfortunately, cDC1s are often rare within the tumor environment, especially 
relative to the other expanding myeloid populations29,81. We asked whether this might 
be due to a systemic depletion due to alteration in myeloid-DC development (Fig. 1.3).  
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IRF8-mediated Regulation of Myeloid Differentiation and Dendritic Cell 
Development 
 IRF8 expression is required for cDC1 development, and also controls expansion 
of granulocytes and immature monocytes. IRF8 is expressed at low levels in the GMP 
and gradually upregulated on a population level as differentiation moves towards the 
DC lineage94. When assessed on the single cell level, increased IRF8 expression in 
cells of a certain subset identifies progenitors primed to assume a DC and, later, a 
cDC1 fate79,81,82,94. IRF8 expression drives a maturation and antigen presentation 
program regulating proteins like MHC molecules, co-stimulatory molecules and antigen 
presentation machinery86,95. IRF8 is required for differentiation of cDC1s, where it is 
further upregulated and then stabilized by expression of BATF384,86. Further, IRF8 
extinguishes granulocyte potential by preventing C/EBPα from binding to chromatin and 
driving a granulocyte transcriptional program96,97. In concordance with this molecular 
program, IRF8-/- mice experience a myeloproliferative disorder, including an expansion 
of granulocytes, and fail to produce cDC1s96,98.  
 IRF8 is known to be downregulated in myeloid cell during cancer. IRF8 was first 
found to be downregulated in granulocyte progenitor in tumor-bearing mice. This led to 
an expansion of granulocytes and immature monocytes, that reduced responses to 
checkpoint blockade in a breast cancer model98,99. This study identified GCSF as a 
regulator of Stat3 phosphorylation, which led to IRF8 downregulation98. Given the 
importance of IRF8 in DC and specifically cDC1 development and the important role of 
cDC1s in the control of cancer, we asked whether a similar molecular regulation was at 
play during cancer in DC progenitors. 
 
 
13 
1.1 Figures 
 
Figure 1.1.  
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Figure 1.1. T cell activation in cancer 
 
(a) T cell activation is mediated by many signals. First, antigen must be taken up by an 
antigen presenting cell, processed and present in MHC on the cell surface. This process 
occurs when the antigen presenting cell engulfs antigen and also receives maturation 
signals, such as toll-like receptor (TLR) signaling. T cells with a matching T cell receptor 
(TCR) must recognize antigen presented on MHC. Then, the T cell must receive a 
positive signal through it CD28 receptors by binding to B7-1 or B7-2 on the surface of 
the antigen presenting cell. T cells then receive co-stimulatory signals to further support 
T cell activation. CD4+ T cells also receive cytokine signals from antigen presenting 
cells to influence the type of CD4+ T cells that is produced. Furthermore, CD4+ T cells 
can support activation of CD8+ T cells by providing cytokine signals like IL-2 to promote 
activation and proliferation15.  (b) During cancer, many of these signals are interrupted. 
First, different myeloid populations in the tumor compete for antigen uptake, meaning 
the best antigen presenters may not be the primary population taking up tumor-
associated antigen. Cancer does not always provide signals to mature antigen 
presenting cells, so even if antigen is taken up, it may not be present on MHC for T cell 
recognition. Furthermore, if antigen is presented, co-stimulation may be interrupted 
through binding of CTLA-4 to B7-1 or B7-2 rather than CD28, sending a negative signal 
and preventing T cell activation. Antigen presenting cells will also express lower levels 
of co-stimulatory receptor limiting the support of T cell activation. Antigen presentation 
cells in tumors may also produce cytokines to induce immune suppressive, instead of 
immune stimulatory, CD4+ T cells. Finally, if an activated T cell does make it into the 
tumor tissue, it will likely encounter checkpoint molecules such as PDL1 present on the 
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surface of myeloid populations or tumor cells. This signal will inactivate the T cells and 
ultimately lead to T cell death17-19,26-30.    
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Figure 1.2.  
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Figure 1.2. Cancer-induced myelopoiesis 
 
Myeloid cells differentiate from progenitors found in the bone marrow (BM). The 
hematopoietic stem cell (HSC) is upstream of the granulocyte-macrophage progenitor 
(GMP), which maintains granulocyte, monocyte and DC potential. GMPs differentiate 
either into immature granulocytes or into the macrophage dendritic cell progenitors 
(MDPs), which maintains monocyte and dendritic cells potential. MDPs can differentiate 
into monocytes or common dendritic cell progenitors (CDPs), which are committed to 
the DC lineage. CDPs can produce plasmacytoid dendritic cells (pDCs) or pre-DCs, 
which are committed to the common dendritic cell (cDC) lineage. Monocytes transverse 
into the periphery through the blood where they can function or differentiate into 
macrophages once they reach peripheral tissues. Granulocytes mature as they move 
into the blood and can infiltrate into tissues. Pre-DCs move through the blood into 
tissues where they can fully differentiated into cDC1s or cDC2s, two subsets of cDCs. 
During cancer and other inflammatory insults, inflammatory cytokine signaling 
influences myeloid differentiation. Under these conditions, granulocytes and monocytes 
are expanded from progenitors in the BM. The new granulocytes and monocytes can 
maintain a more immature phenotype as they move into the periphery. The 
consequence this has on DC differentiation is not well understood18,43,47,73. 
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Figure 1.3.  
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Figure 1.3. cDC1 identity and functions  
 
cDC1s differentiation is driven by the transcription factors BATF3, IRF8 and Id2. They 
are capable of cross presentation and specialize in activation of CD8+ T cells. They are 
further important for reactivation of memory T cells and transport of antigen into the 
lymph node. Given these functions, they are important for anti-tumor immunity including 
tumor control and response to chemo- and immune-therapy.  
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Chapter 2: Breast and Pancreatic Cancer 
Interrupt IRF8-Dependent Dendritic Cell 
Development to Overcome Immune 
Surveillance 
2.1 Introduction 
To subvert immune surveillance, solid tumors disrupt tumor-targeted immune 
responses. Conventional dendritic cells (cDCs) support anti-tumor adaptive immunity by 
stimulating T cells, but cDCs often fail to accumulate in the tumor microenvironment29,81. 
Furthermore, those cDCs found in the tumor can be immature and are therefore less 
effective in antigen presentation and T cell stimulation19,88,100,101. Solid tumors also 
interfere with anti-tumor immune responses by stimulating immature granulocyte and 
monocyte production from bone marrow (BM) progenitors. Expanded myeloid cells are 
recruited to tumors where they can maintain an immature phenotype or differentiate into 
tumor-associated macrophages. All of these populations can suppress anti-tumor CD8+ 
T cells as well as promote tumor progression through support of angiogenesis and 
metastasis18,43,47,102. Interestingly, cDCs are produced from the same BM progenitors as 
the expanding populations of granulocytes and monocytes59,61. Although granulocyte 
and monocyte differentiation is known to be dysregulated in cancer18,43,47,102, we do not 
fully understand how tumors affect cDC differentiation. Because of their common origin, 
we hypothesized that tumor-induced expansion of immature granulocytes and 
monocytes occur at the expense of cDC differentiation. 
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Because of their role in activating CD8+ T cells, cDC1s have been implicated in 
supporting the T cell response against solid tumors. CD103+ cDC1s are known to cross 
present antigen to activate CD8+ T cells and secrete factors that attract T cells into the 
tumor85,89,91. Furthermore, CD103+ cDC1s are important for transporting antigen into the 
draining lymph nodes, supporting T cell activation and expansion20,81,90. Given these 
functions, it is understandable that CD103+ cDC1s have been implicated in initiation and 
maintenance of CD8+ T cell responses against tumors. CD103+ cDC1s are required to 
restrain tumor growth and support response to CD8+ T cell-mediated chemo- and 
immune-therapies in multiple mouse models of solid tumors. In patients, intratumoral 
CD141+ cDC1 numbers correlate with better outcomes in many types of solid tumors, 
including breast cancer (BC)19,29,30,81,85,92,93. Thus, cDC1s are important mediators of the 
anti-tumor CD8+ T cell response and can function to control tumor progression in mice 
and humans. 
 Given their important role in supporting anti-tumor immunity, we inquired 
whether tumor progression affects the generation of cDCs. Recent work has shown that 
after committing to the granulocyte, monocyte, or cDC lineage, cDC precursors can 
commit to the cDC1 subset during differentiation before leaving the BM64,82,84,103,104. 
Given that differentiation choice can be made outside the tumor microenvironment, we 
hypothesized that systemic changes induced by tumors might impair cDC, and further 
cDC1, commitment in the BM, and subsequently influence cDC1s in the periphery and 
anti-tumor immunity. In this study, we show that tumors interrupt cDC, and specifically 
cDC1, differentiation in BC and pancreatic ductal adenocarcinoma (PDAC) mouse 
models and patients. This interruption reduces the systemic cDC1 pool, negatively 
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impacts CD8+ T cell immunity, and correlates with poor patient outcome. Our data 
illustrate a new mechanism by which tumors subvert anti-tumor immunity via 
dysregulation of cDC1 differentiation. 
2.2 Results 
Breast and pancreatic cancer patients have reduced cDC differentiation in the 
bone marrow 
cDCs are important for initiating and sustaining anti-tumor T cell responses20,29,81. 
To understand the impact of tumors on development of cDCs, we profiled BM samples 
from human BC and PDAC patients with localized disease and no prior therapy. We 
analyzed the following cDC progenitors: macrophage-dendritic cell progenitors (MDPs), 
which retain monocyte/macrophage potential; common dendritic cell progenitors, which 
retain plasmacytoid DC potential; and pre-DCs, which are committed to the cDC 
lineage. Relative to BM from healthy controls, BM from both BC and PDAC patients had 
decreased numbers of CDPs and pre-DCs. MDPs were significantly reduced in BC 
patients but not PDAC patients (Fig. 2.1a-b, Supplementary Fig. 2.1a, Supplemental 
Table 2.1). These data suggest the defect in BM progenitors is strongest and most 
consistent after progenitors start to commit to the cDC lineage. We also analyzed cells 
of the cDC subsets, cDC1s and cDC2s, found in the BM. Patient populations showed a 
decrease in CD141+ cDC1s and CD1c+ cDC2s (Fig. 2.1a-b). As illustrated in Fig. 2.1a, 
cDC1s are rare in the BM but are dramatically reduced in BC and PDAC patients. We 
validated these findings using a second cohort of BC patients (Supplementary Fig. 
2.1c). In contrast to the cDC lineage, an expansion of BM immature granulocytes 
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(CD11b+CD33HiCD14-CD15+), potentially a subset of myeloid-derived suppressor cells 
(MDSCs), was observed in both cancer types (Fig. 2.1b). This result is in agreement 
with published observations in several other solid tumor types43,105-108. To determine if 
the reduction in cDCs extended into the periphery, where cDCs are thought to 
function71,85, we analyzed BC and PDAC patient blood samples and found reduced pre-
DC numbers and increased immature granulocyte numbers relative to healthy controls 
(Fig. 2.1c). We validated these findings in a second cohort of PDAC patient 
(Supplementary Fig. 2.1d). Together, these data suggest that cancer results in 
decreased cDC lineage cells in the BM and decreases in the systemic pool of pre-DCs. 
Previous studies have shown that CD141+ cDC1 numbers and functions in the 
tumor are predictive of patient outcome19,29,109, prompting us to assess whether 
changes in CD141+ cDC1s in the BM prior to treatment or resection were also predictive 
of response to therapy. We observed higher numbers of CD141+ cDC1s and lower 
numbers of granulocytes (CD45+CD11b+CSF1R-CD15+CD14-) in the BM of BC patients 
who achieved a pathological complete response (pCR) to neoadjuvant chemotherapy 
(Fig. 2.1d, Supplemental Table 2.1). Notably, CD1c+ cDC2 numbers were not 
predictive of pCR, suggesting the predictive nature is specific to the CD141+ cDC1 
subset (Supplementary Fig. 2.1e). These findings demonstrate that tumor-induced 
decreases in CD141+ cDC1 development in the BM could be an important indicator of 
patient immune competency and response to therapy.  
Primary breast and pancreatic tumors systemically decrease cDC1s 
To more carefully study changes in cDC development during cancer progression, 
we evaluated three distinct genetic mouse models and four syngeneic orthotopic mouse 
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models of BC and PDAC. Similar to the human cancer patients, we found six of these 
seven models had reductions in absolute numbers of BM CD24+ cDC1s and most had 
reductions in the absolute number of BM pre-DCs (Fig. 2.2a-c, Supplementary Fig. 
2.3c-f). To further investigate the cDC lineage in tumor-bearing mice, we employed 
PyMT-B6, a cell line derived from the genetic MMTV-Polyoma Middle T (PyMT) 
mammary tumor mouse model on the C57BL/6 background. Consistent with the patient 
data, mice bearing end-stage orthotopic PyMT-B6 mammary tumors showed no change 
in MDPs but a modest reduction in CDPs (Fig. 2.2b, Supplementary Fig. 2.2a). This 
finding suggests that tumors impact components of the cDC1 lineage. Unlike cDC1s, 
cDC2s were not consistently decreased in the BM of tumor-bearing mice across several 
models (Fig. 2.2a-c, Supplementary Fig. 2.3c-f). In contrast to cDC1s, 
Ly6G+Ly6C+CSF1R+ immature granulocytes and Ly6G+CSF1R- mature granulocytes 
expand in the BM (Fig. 2.2b, Supplementary Fig. 2.2a). In addition, the changes in 
cDC progenitors and granulocytic populations were consistent in the genetic models of 
BC and PDAC: MMTV-PyMT and KPC, respectively (Supplementary Fig. 2.3a-b). 
Together, these data suggest that solid tumors reduce the number of cells that make up 
the cDC lineage, including cDC1. 
Specific reductions in the cDC progenitors and cDC1s suggest a selective 
interruption of cDC1 development. Recent data show that pre-DCs can commit to the 
cDC1 subset before leaving the BM, rather than receiving influence from factors at a 
peripheral site82,84,103. To evaluate this phenomenon, we assessed the number of DC1-
committed pre-DCs (pre-cDC1s) in the BM using the gating strategy defined by 
Grajales-Reyes et al. employing the Zbtb46-GFP mouse84. We found that pre-cDC1s 
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were decreased by 80% in the BM of tumor-bearing mice, which is a more substantial 
decrease than the reduction in the broader pre-DC population (Fig. 2.2d). These data 
suggest that tumors not only reduce the number of cDC progenitors, but also reduce the 
commitment of pre-DCs to the cDC1 lineage in the BM. 
To determine if changes in cDC1 progenitors result in systemic alterations in the 
pool of available cDCs, we analyzed circulating pre-DCs. We found fewer pre-DCs and 
more granulocytes in the blood of tumor-bearing mice relative to controls (Fig. 2.2e and 
f, Supplementary Fig. 2.2b). Similar observations were seen in the genetic BC model, 
MMTV-PyMT, and genetic PDAC model, KPC (Fig. 2.2g), as well as two additional 
orthotopic BC and PDAC models (Supplementary Fig. 2.3d-e). These changes in the 
pool of circulating pre-DCs correlated with reduced numbers of CD103+ cDC1s in the 
uninvolved lymph nodes of tumor-bearing mice (Fig. 2.2h, Supplementary Fig. 2.2c). 
Congruent with observations in BC and PDAC patients, these data show that mouse 
models of BC and PDAC, independent of genetic driver and strain, have systemically 
reduced numbers of cDC precursors and cDC1s. Interestingly, plasmacytoid dendritic 
cells (pDCs) were decreased in the BM, but circulating pDCs were not decreased 
(Supplementary Fig. 2.3g), suggesting they may be regulated differently.  
 Research has shown that cDCs turn over at a high rate in tissues and require BM 
progenitors to provide new cDC177. To determine if the decreased pool of circulating 
pre-DCs would result in altered recruitment and antigen presentation at new sites of 
inflammation, we measured the recruitment of CD103+ cDC1s in the context of a tumor. 
PyMT-B6 mammary tumors were established in the 4th lower mammary fat pads. Then, 
a matrigel plug containing poly I:C and ovalbumin (OVA)-Texas Red conjugate was 
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implanted in the contralateral 2nd upper mammary fats pads of tumor-bearing and 
control mice. We found that the presence of the primary tumors resulted in decreased 
numbers of CD103+ cDC1s recruited into the matrigel plug and decreased numbers of 
migratory CD103+ cDC1s in the draining lymph node  (Fig. 2.2i, Supplementary Fig. 
2.2d). These changes in cDC1 recruitment correlated with reduced numbers of 
ovalbumin (OVA)-specific CD8+ T cells (CD3+CD8+Dextamer+) in the matrigel plug (Fig. 
2.2i). To verify that the reduced number of cDC1s in the poly-IC plug was due to a 
decreased pool of circulating pre-DCs rather than changes in recruitment cytokines, we 
measured recruitment of CD103+ cDC1s to a matrigel plug containing the recruitment 
factor Ccl4, which is known to be downregulated in some tumor types92. Again, we saw 
a defect in CD103+ cDC1s recruited to the Ccl4-containing matrigel plug in tumor-
bearing mice (Supplementary Fig. 2.3h). Similarly, we found there was no change in 
pre-DC Ccr5 expression in tumor-bearing mice (Supplementary Fig. 2.3i). Together, 
these data suggest that tumor-induced repression of cDC development results in a 
reduced pool of circulating pre-DCs and a subsequent reduction in recruitment of 
cDC1s to new sites of inflammation and impaired priming of CD8+ T cells.  
Tumor exposed myeloid progenitors have impaired cDC1 developmental potential  
The contrasting increases in granulocytes and decreases in cDC progenitors led 
us to hypothesize that tumors alter the differentiation potential of common myeloid 
precursor cells. To test this, we isolated CD45.1+Lin-cKit+ScaI- myeloid progenitors 
(MPs). This cell population maintains granulocyte, monocyte and cDC potential and 
contains granulocyte-macrophage progenitors (GMPs)61. The MPs were transferred into 
tumor-free controls or mice bearing PyMT-B6 tumors. We found that CD45.1+ MPs 
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transferred into tumor-bearing mice differentiated into fewer CDPs, pre-DCs, and cDC1s 
in the BM, but more granulocytes in both the BM and blood (Fig. 2.3a). Fewer CD8α+ 
cDC1s and more granulocytes were included in the CD45.1+ products in the spleens of 
tumor-bearing hosts. Although CD45.1+ monocytes were not consistently increased in 
each organ, they accumulated in the spleen (Supplementary Fig. 2.4a). These data 
suggest that tumors preferentially drive the differentiation of shared progenitors to 
granulocytes at the expense of cDC1 development. To determine if exposure to tumors 
in vivo programs BM progenitor cells to resist cDC1 differentiation, we isolated MPs, 
MDPs, or CDPs from tumor-free and PyMT-B6 tumor-bearing mice. When cultured in 
FMS-like tyrosine kinase 3 ligand (Flt3L), we found MPs, MDPs, and CDPs isolated 
from tumor-bearing mice were less able to differentiate into cDC1s compared to those 
cells isolated from tumor-free mice (Fig. 2.3b). Of these progenitors, CDPs appeared to 
be most impaired in their capacity to differentiate into cDC1s. Of note, MPs from tumor-
bearing mice but not from tumor-free mice differentiated into granulocytes even in the 
absence of granulocyte differentiation factors (Supplementary Fig. 2.4c). This result 
suggests MPs from tumor-bearing mice are intrinsically primed to differentiate into 
granulocytes at the expense of cDC1s. As expected, MDPs and CDPs from tumor-free 
or tumor-bearing mice did not have granulocyte differentiation potential 
(Supplementary Fig. 2.4b-c). Taken together, these data suggest that tumors alter 
myeloid progenitor fate by increasing their potential to differentiate into granulocytes at 
the expense of cDC1 production. 
To further investigate the differences in progenitors from tumor-free and tumor-
bearing mice, we profiled the gene expression in GMPs, MDPs and CDPs. We found 
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GMPs, MDPs, and CDPs from tumor-bearing mice failed to upregulate proteins 
indicative of the cDC program (e.g. Irf8, Zbtb46, Cd209a, Spib, Batf3, and Bcl11a). This 
result is in contrast to the increased expression of markers indicative of a granulocyte or 
monocyte fate (e.g. Cebpe, Gfi1, Cebpa, Id1, Cebpb and Mafb) (Fig 2.3c). We further 
profiled MDPs and CDPs from tumor-bearing mice by microarray to look for global 
changes in gene expression. We found the CDPs from tumor-bearing mice clustered 
closer with MDPs than did CDPs from tumor-free mice (Fig. 2.3d, Supplemental Table 
2.2-3). DAVID analysis showed that the upregulated genes were enriched for biologic 
process terms like inflammatory response, myeloid cell differentiation, cell cycle 
regulation, and cytokine secretion, whereas downregulated genes were enriched for 
biologic process terms like transcriptional regulation, MHC class II protein complex 
binding, differentiation and covalent chromatin modifications (Supplemental Table 2.4). 
Overall, these data suggest a failure in progenitors to upregulate the cDC program, 
while favoring the granulocytic and monocytic programs in tumor-bearing mice.  
To determine if the reduction in cDC1 differentiation potential could impact tumor 
immunity and tumor progression, we measured the ability of progenitors isolated from 
tumor-bearing or tumor-free mice to control tumor growth in BATF3-/- mice. We chose 
BATF3-/- mice because they lack functional cDC1s85 but have no defect in granulocyte 
number (Supplementary Fig. 2.7c). First, we observed that tumor growth of PyMT-
mCh-OVA, a variant of PyMT-B6 expressing antigenic mCherry and ovalbumin, was 
restrained in wild-type, but not in BATF3-/- mice (Fig. 2.3e). MDPs and CDPs were 
sorted from PyMT-B6 tumor-bearing or tumor-free controls and transferred into BATF3-/-
mice. The recipients were then implanted with PyMT-mCh-OVA. Mice that received 
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MDPs and CDPs from wild-type mice were able to restrain PyMT-mCh-OVA tumor 
growth, similar to wild-type mice, whereas mice that received MDPs and CDPs from 
tumor-bearing mice were not able to restrain tumor growth (Fig. 2.3e). These data 
suggest that progenitors influenced by tumor burden are no longer able to act as a 
source of cDC1s and thus fail to induce anti-tumor immunity and control antigenic tumor 
progression. 
GCSF inhibits cDC1 development by impairing IRF8 expression  
Research has shown that GCSF preferentially expands immature granulocytes 
and monocytes by suppressing IRF8 expression through activation of signal transducer 
and activator of transcription 3 (Stat3) in granulocytic-monocytic precursors98,110. 
Because IRF8 is an important transcription factor for cDC1 development, we 
hypothesized GCSF might drive reduced IRF8 expression in cDC progenitors leading to 
impaired cDC1 differentiation86,96,111. In support of this notion, our expression profiling 
demonstrated that Irf8 mRNA was downregulated in cDC progenitors from tumor-
bearing mice (Fig. 2.3c). Additionally, we found IRF8 protein was reduced in tumor-
bearing mouse MDPs, CDPs, and pre-DCs (Fig. 2.6a). Further, we analyzed IRF8 
target gene expression in GMPs, MDPs, and CDPs and found that, relative to controls, 
tumor-bearing mice had decreased mRNA expression of multiple major 
histocompatibility (MHC) molecules, as well as TapBP, Tap2, Batf3, and Pml (Fig. 2.3c, 
2.6b). In contrast, Id2, another regulator of cDC1 development was not reduced 
(Supplementary Fig. 2.6a)77. To understand if downregulation of IRF8 is responsible 
for some of the gene expression changes in the microarray analysis (Fig. 2.3d), 
differentially expressed genes between control and tumor-bearing mice were compared 
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to genes that are differentially expressed in IRF8-/- myeloid progenitors96,98. We found 
tumor-regulated genes were enriched for genes regulated in IRF8-/- myeloid progenitors 
(Supplementary Fig. 2.6b). In keeping with the ability of GCSF to downregulate IRF8 
through STAT3 activation98, we observed that phosphorylated STAT3 (pSTAT3) was 
elevated in MDPs, CDPs, and pre-DCs from tumor-bearing mice (Fig. 2.6c).  
To determine if these changes also occur in human cancer patients, we analyzed 
IRF8 expression in human BM and found that IRF8 was downregulated in both BC and 
PDAC patients compared to healthy controls (Fig. 2.6d). Additionally, the extent of IRF8 
downregulation correlated with the decrease in BM pre-DCs in patients (Fig. 2.6e). We 
also found IRF8 expression was decreased in the blood pre-DCs of pancreatic cancer 
patients (Fig. 2.6f) and the extent of IRF8 downregulation correlated with blood pre-DC 
numbers (Fig. 2.6g). Because IRF8 is a molecular marker of pre-DCs committed to the 
cDC1 lineage, these data also suggest that patients have reduced numbers of 
circulating pre-cDC1s relative to healthy controls. We next assessed if downregulation 
of IRF8 in circulating pre-DCs impacted patient outcome and found patients with low 
IRF8 expression in circulating pre-DCs had decreased recurrence-free and overall 
survival (Fig. 2.6h). These results suggest that IRF8 expression is modulated in human 
cancers and may be an indicator of cDC1 development and patient outcome. 
To confirm that GCSF was upstream of IRF8 suppression, we measured IRF8 
expression in cDC progenitors from tumor-bearing mice following GCSF neutralization. 
We found IRF8 expression was recovered in the MDP, CDP, and pre-DCs following 
anti-GCSF immunoglobulin Gs (IgGs) treatment (Fig. 2.7a). Furthermore, IRF8 
expression was, again, down-regulated in progenitors from PyMT-B6 tumor-bearing 
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mice but was not downregulated in progenitors from PyMT-B6 GCSFKO mice 
(Supplementary Fig. 2.5e). To show GCSF was acting directly on progenitors to 
modulate IRF8 expression, we treated MPs, MDPs, and CDPs alone in vitro with GCSF 
or GCSF+Flt3L. We found Irf8, as well as its target gene Batf3, were downregulated in 
both conditions relative to controls (Fig. 2.7b). Interestingly, Flt3L treatment did not 
drive IRF8 expression above controls (Supplementary Fig. 2.6c), suggesting Flt3L and 
GCSF act through different mechanisms to modulate cDC1 differentiation. To determine 
if downregulation of IRF8 is necessary for GCSF to impair cDC1 differentiation, we 
investigated if IRF8 overexpression would make MPs insensitive to GCSF. Without 
IRF8-overexpression, GCSF drove down Flt3L-mediated cDC1 differentiation, similar to 
the results shown in Fig. 2.4e. However, IRF8 overexpression rendered MPs insensitive 
to GCSF, and their cDC1 differentiation was comparable to Flt3L alone conditions (Fig. 
2.7c). These data suggest GCSF must modulate IRF8 expression to impact cDC1 
differentiation.  
IRF8 and cDC1s are necessary for anti-tumor CD8+ T cell responses 
To determine whether suppression of cDC1 differentiation was detrimental to 
anti-tumor immunity, we measured tumor-specific T cell activation in the presence or 
absence of an established tumor. To accomplish this, PyMT-B6 tumors, referred to here 
as the “primary tumor,” were established in the lower mammary fat pad. A secondary 
tumor using the PyMT-mCh-OVA cell line was then implanted into the upper mammary 
fat pad of the same mouse. We observed reduced recruitment of CD103+ cDC1s to the 
secondary tumor site and draining lymph nodes of primary tumor-bearing mice (Fig. 
2.8a). This result is consistent with the reduction in the available pool of circulating pre-
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cDC1s in tumor-bearing animals (Fig. 2.2i). To test if reduced recruitment of CD103+ 
cDC1s was functionally relevant, we measured OVA-specific CD8+ T cells within the 
secondary tumor site and the secondary tumor draining lymph nodes and found the 
OVA-specific CD8+ T cells were reduced in both sites of primary tumor-bearing mice 
compared to controls (Fig. 2.8a). To specifically implicate IRF8 and cDC1s in this 
decreased CD8+ T cell response, we employed IRF8-/- and Batf3-/- mice, both of which 
have impaired cDC1 differentiation85,86,111. In these knockouts, we observed reduced 
numbers of tumor-specific CD8+ T cells comparable to the primary tumor-bearing mice. 
In addition, this reduction was not further decreased by the presence of primary tumors 
(Fig. 2.8a). These data suggest that tumor-induced reductions in cDC1 development 
have a functional consequence on tumor-specific CD8+ T cell responses that could 
contribute to reduction in anti-tumor immunity. 
 Tumor-induced reductions in IRF8 also expand immature granulocytes that are 
known to have immune suppressive functions and can otherwise promote tumor 
progression43,112,113. We sought to determine the contributions of immature granulocyte 
expansion to reduced number of cDC1s and reduced anti-tumor CD8+ T cell responses. 
To test if cDC1 depletion was regulated through granulocyte expansion, mice were 
treated with anti-Ly6G IgGs. Ly6G-depletion did not reverse the defect in BM pre-DCs 
and cDC1s and did not recover IRF8 expression in BM progenitors (Supplementary 
Fig. 2.7a). To show that immature granulocytes were not mediating CD8+ T cell 
suppression beyond the loss of cDC1s in this model, we neutralized Ly6G in the context 
of the secondary tumor experiment described above. We found Ly6G depletion did not 
recover tumor-specific CD8+ T cells in the secondary tumor nor the draining lymph node 
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(Fig. 2.8a). Similarly, we showed anti-Ly6G depletions did not recover CD103+ cDC1 
recruitment to a matrigel plug containing poly I:C and OVA-TxRd conjugate, a 
secondary site of inflammation, in primary tumor-bearing mice. Additionally, CD103+ 
cDC1s were not recovered in the draining lymph node and OVA-specific CD8+ T cells 
were not recovered in the matrigel plug (Supplementary Fig. 2.7b). To test whether the 
loss of IRF8 had a functional consequence on tumor outgrowth by acting through the 
loss of cDC1s rather than the expansion of granulocytes, we measured the growth of 
PyMT-mCh-OVA tumors in IRF8-/- mice, which lack cDC1s and have expanded 
granulocytes, and Batf3-/- mice, which only lack functional cDC1 (Supplementary Fig. 
2.7c)85,96. We found that tumors grew at the same rate in Batf3-/- as IRF8-/- mice, but 
that this rate was significantly faster than wild-type controls (Fig. 2.8b). Also, we 
neutralized Ly6G in IRF8-/- mice and measured PyMT-mCh-OVA tumor growth and 
found tumors grew at similar rates (Fig. 2.8c). These findings suggest that the loss of 
IRF8 can promote tumor growth by suppressing cDC1s rather than solely through the 
expansion of granulocytes. Together, these results show granulocytes do not act as an 
intermediate to inhibit cDC1 differentiation and the functional effects on antigen specific 
CD8+ T cells and tumor control are primarily mediated by cDC1s, not granulocytes, in 
this model. 
GCSF neutralization overcomes resistance to Flt3L-based dendritic cell 
mobilization  
Our data suggest that exposure to tumor-derived GCSF can impair BM 
progenitors in their ability to generate cDC1s. As Flt3L therapy has been developed for 
use in patients to bolster cDC numbers and function81, we asked if the impairment in 
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cDC development could be rescued by Flt3L treatment in vivo or if GCSF neutralization 
was necessary for maximum efficacy of this therapy. To accomplish this we treated 
tumor-free or mice bearing a 1-cm+ diameter PyMT-B6 tumor with Flt3L +/- anti-GCSF 
IgGs for two weeks. Consistent with previous reports81, we observed that in tumor-free 
mice treated with Flt3L expanded pre-DCs, cDC1 and cDC2 in the BM and pre-DCs in 
the blood (Fig. 2.9a-b). We also observed that combined treatment with Flt3L and anti-
GCSF IgGs did not significantly up regulate pre-DC or cDC numbers in tumor-free mice 
(Fig. 9a-b). This result is consistent with the finding that GCSF is expressed at lower 
levels under non-pathologic conditions (Fig. 2.4a). Similar to our other experiments, 
pre-DCs and cDC1s numbers were decreased in the BM and blood of PyMT-B6 tumor-
bearing mice compared to controls (Fig. 2.9a-b). We also found that although Flt3L 
could expand pre-DCs and cDC numbers in the BM and blood in the presence of 
tumors, but this expansion was significantly limited compared to tumor-free mice in that 
pre-DC or cDC1 numbers only reached levels comparable to untreated tumor-free mice 
(Fig. 2.9a-b). These data suggest that BM progenitors in tumor-bearing mice are 
resistant to Flt3L-induced cDC1 differentiation, which is consistent with our in vitro 
results (Fig. 2.3b). Furthermore, anti-GCSF IgGs and Flt3L synergized to recover pre-
DC and cDC1 numbers in tumor-bearing mice (Fig. 2.9a-b). Because our data suggest 
that GCSF impacts IRF8 levels, we analyzed the impact of Flt3L and anti-GCSF IgGs 
on IRF8 levels in DC progenitors. In tumor-bearing mice, in which IRF8 is 
downregulated, neutralizing GCSF restores IRF8 levels to tumor-free mouse conditions 
in BM progenitors. Importantly, neutralizing GCSF also increased IRF8 levels in pre-
DCs (Fig. 2.9c, Supplementary Fig. 2.7d). These findings suggest neutralizing tumor-
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induced GCSF is required to recover IRF8 expression, which is necessary for cDC1 
differentiation.  
To determine if these changes in lymphoid tissues translated to increased tumor 
immunity we analyzed tumor tissues. As previously reported81, Flt3L increases both 
tumor-infiltrating CD103+ cDC1s and CD11b+ cDC2s, but this expansion of cDC1s was 
modest in this model (Fig. 2.9d). When Flt3L was combined with anti-GCSF IgGs, 
tumor infiltration of CD103+ cDC1s, but not CD11b+ cDC2s, was increased by more 
than two-fold and this increase correlated with substantially more CD8+ T cells. 
Together, these data shows that GCSF neutralization supports Flt3L-mediated 
expansion and mobilization of cDC1 and suggest this activity is facilitated in part by 
restoring IRF8 expression and commitment to the cDC1 lineage. 
 Given these results, we hypothesized anti-GCSF IgGs would bolster DC-based 
immunotherapeutic strategies in established tumors. Mice bearing well-established 1-
cm+ diameter PyMT-B6 tumors were treated with Flt3L + poly I:C + anti-PD1 IgGs +/- 
anti-GCSF IgGs. Mice treated with combined Flt3L + poly I:C + anti-PD1 IgGs did not 
have a significant increase in survival relative to vehicle-treated controls. By contrast, 
survival was significantly extended in mice treated with anti-GCSF IgGs + Flt3L +poly 
I:C + anti-PD1 IgGs compared with mice treated with vehicle alone or Flt3L+poly I:C+ 
anti-PD1 IgGs (Fig. 2.9e, Supplementary Fig. 2.7e). This effect was not seen in 
similarly treated IRF8-/- and BATF3-/- mice, suggesting that this treatment is reliant on 
IRF8 and cDC1 activity (Fig. 2.9e, Supplementary Fig. 2.7e). Together, these data 
suggest that GCSF signaling may need to be inhibited to employ immunotherapy 
effectively in some established tumor settings.  
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2.3 Summary 
 Myeloid differentiation is disrupted in cancer. We show the expansion of 
immature granulocytes and monocytes is at the expense of cDC differentiation. 
Specially cDC progenitors and cDC1s are systemically decreased in breast and 
pancreatic patients, as well as mouse models. This led to a failure of tumor-bearing 
mice to populate new sites of inflammation with cDC1s and this result correlated with a 
deficiency in antigen specific CD8+ T cell responses. The reduction is cDC1s is rooted 
in a true defect in differentiation, as progenitors isolated from tumor bearing mice fail to 
produce cDC1s during in vitro differentiation and normal progenitors transferred into 
tumor bearing mice fail to differentiate into cDC1s in vivo. Further, we found the change 
in differentiation potential is associated with a change in transcriptional profile 
suggesting tumor-bearing mouse progenitors favor granulocyte-monocyte expression 
patterns over cDC expression patterns. We found the interruption in cDC1 differentiation 
had functional implications. Patients who responded to neo-adjuvant chemotherapy had 
a higher number of CD141+ cDC1s in there BM prior to treatment. And, progenitors 
isolated from tumor bearing mice failed to recover tumor control in mice that lack 
functional cDC1s. In total, these data show tumors alter the fate of myeloid progenitors 
to favor granulocyte-monocyte differentiation over cDC differentiation.  
 We identified GCSF as the tumor-derived factor altering the transcriptional profile 
leading to deficiencies in cDC1 differentiation. GCSF derived from tumor cells led to a 
decrease in expression of the transcription factor IRF8, a major driver of cDC and 
specifically cDC1 differentiation87.  The loss of IRF8 is necessary to drive the decrease 
in cDC1 caused by GCSF signaling in DC progenitors. Further, alteration in GCSF 
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levels in IRF8 expression in DC progenitors were also found in patients and, in PDAC, 
predicted outcome.  
 Finally, we showed deficiencies in cDC1 differentiation were detrimental to CD8+ 
T cell responses and response to immunotherapy. The presences of a primary tumor 
was capable of driving down the number of cD103+ cDC1s recruited to a secondary 
tumor site and further, reduced the tumor-specific CD8+ T cell responses. These 
reductions were similar to those seen in mice lacking functional cDC1s. We also found 
the loss of tumor control and tumor-specific CD8+ T cell responses were independent of 
granulocytes. Given the tumor-induced reductions in cDC1 functions, we employed 
strategies to recover CD103+ cDC1s to support response to immune-therapy. Given in 
vitro data showed GCSF could inhibit Flt3L-mediated cDC1 differentiation, we 
hypothesized tumor-derived GCSF would inhibit response to therapeutically relevant 
Flt3L treatment used to bolster response to checkpoint therapy. We found GCSF 
neutralization could synergize with Flt3L treatment to drive cDC1 differentiation and 
CD103+ cDC1s in the tumor tissue. This result correlated with increased overall survival 
in mice treated with anti-GCSF+Flt3L+poly I:C+anti-PD1, compared to vehicle or 
Flt3L+poly I:C+anti-PD1 treatment.  
 In summary, these data have elucidated a new mechanism of immune evasion 
employed by tumors, wherein tumor-induced inflammatory cytokines drive reductions in 
cDC1 development.  
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2.4 Methods 
Human Bone Marrow, Peripheral Blood and Tumor Samples 
BM and peripheral blood was obtained from patients diagnosed with locally advance or 
unresectable pancreatic ductal adenocarcinoma or clinical stage II/III breast cancer at 
the Barnes-Jewish Hospital (St. Louis, MO, USA) from 2004 to 2014 and were followed 
for recurrence and survival in a prospectively collected database. Samples were 
collected under informed consent in concordance with Institutional Review Board (IRB) 
approval (IRB protocol numbers 201102244, 201101961, 201108117). At the time of 
collection, these patients had received no prior cancer-related treatment. Healthy donor 
BM and blood were collected from cancer-free volunteers. Blood was collected into 
vacuum tubes containing Heparin or EDTA (BD Bioscience). Cells were isolated by 
Ficoll-density centrifugation and frozen in fetal bovine serum with 5% dimethyl sulfoxide. 
BM from PDAC patients and BC cohort 1 patients was isolated as previously 
described114,115. BM from patients in BC cohort 2 was similarly obtained and stored but 
was not subjected to Ficoll-density centrifugation.  Breast tumor biopsies were from 
patients at the time of metastatic diagnosis under informed consent in concordance with 
IRB approval (IRB protocol number 201102394). Primary pancreatic adenocarcinoma 
tissues were collected during surgical resection and verified by standard pathology (IRB 
protocol number 201108117).  
Cell Lines and Constructs 
The PyMT-B6 murine mammary tumor cell line was derived from the mammary tumor 
tissue obtained from an end stage MMTV-PyMT C57BL/6 mouse by our laboratory. The 
cell line was validated for PyMT expression; pan-keratin positivity; and Vimentin, SMA 
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and CD45 negativity. A subset of this cell line was labeled with click beetle red 
luciferase-mCherry reporter and transduced to express Ovalbumin (PyMT-mCh-OVA). 
PyMT-B6-GCSFKO was made using the lentiCRISPR v2 vector. Virus was packaged 
using 293T cells and helper plasmids pCMV-DR8.2 and pCMV-VSVG. Csf3 gRNA 
sequences used were aggacgagaggccgttcccc, ctacaagctgtgtcaccccg, and 
ggagacggctcgccttgctc. Clones were selected and screened by sequencing for depletion 
of the Csf3 gene. The 4T1-FL-GFP murine mammary tumor cell line was obtained from 
Dr. Katherine Weilbaecher’s laboratory, originally from Dr. David Piwnica-Worms 
(Washington University in St. Louis, MO, USA). It had been previously modified to 
express firefly luciferase and green fluorescent protein, as previously described116. The 
Pan02 murine pancreatic tumor cell line was obtained from Dr. David C. Linehan 
(University of Rochester, NY, USA). The KP 1.0 murine pancreatic tumor cell line was 
derived from the pancreatic tumor tissue obtained by our laboratory from an end stage 
KPC mouse and has been previously reported117. All cell lines were maintained in 
Dulbecco’s Modified Eagle Medium (DMEM) (Lonza) supplemented with 10% fetal 
bovine serum (Atlanta Biological) and penicillin/streptomycin (Gibco). All cell lines tested 
negative for mycoplasma.  
Genetic and Orthotopic Mouse Models 
Mice were maintained in the Washington University Laboratory for Animal Care barrier 
facility. All studies were approved by the Washington University School of Medicine 
Institutional Animal Studies Committee. MMTV-PyMT FVB/N were obtained from The 
Jackson Laboratory and have been previously described118. Mice were analyzed at end-
stage, defined as approximately three months of age or when tumors reached >1.5cm 
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diameter. KPC (p48-Cre;LSL-KrasG12D;Trp53flox/+ C57BL/6) and KPPC (p48-Cre;LSL-
KrasG12D;Trp53flox/flox C57BL/6) component mice were either obtained from The Jackson 
Laboratory (Kras and p53) or from Dr. Sunil Hingorani (p48, University of Washington, 
WA, USA) and have been previously described117. KPC experiments were performed 
with mice of mixed genders and mice were analyzed at end-stage, defined as 
approximately six months of age or when tumors reached 1.0 cm, the animal 
experienced >15% weight loss or other absolute survival event. For genetic models, 
aged matched littermates lacking oncogene expression were used as tumor-free 
controls. Zbtb46-GFP (B6.129S(C)-Zbtb46tm1.1Kmm/J), IRF8-/- (B6(Cg)-Irf8tm1.2Hm/J) and 
Batf3-/- (B6.129S(C)-Batf3tm1Kmm/J) mice in the C57BL/6 background were obtained from 
The Jackson Laboratory and have been previously described84,85,119. A total of 2.5x105 
PyMT-B6, PyMT-mCh-OVA or 4T1-FL-GFP cell lines were orthotopically implanted in 
low growth factor matrigel (Cultrex) into the mammary fat pad 4/5, while 2x105 Pan02 
cells were orthotopically implanted in low growth factor matrigel (Cultrex) into the 
pancreas. All cell lines were implanted into C57BL/6 mice, except 4T1, which was 
implanted into BalbC mice. PDAC mouse models were analyzed at end-stage, defined 
as tumors reaching 1.0 cm, the animal experienced >15% weight loss or other absolute 
survival event. BC mouse models were analyzed at end-stage, defined as tumors 
reaching 1.5cm, the animal experienced >15% weight loss or other absolute survival 
event. For secondary tumor experiments, 5x105 PyMT-mCh-OVA cells were implanted 
into mammary fat pad 2/3 when the 2.5x105 PyMT-B6 cells implanted into the mammary 
fat pad 4/5 produced a tumor 1.0 cm in diameter, or into mammary fat pad 2/3 of non-
primary tumor-bearing matched controls. Mice were analyzed 1 week after secondary 
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tumor implant. For anti-Ly6G IgGs treated arm, anti-Ly6G IgGs treatment, as described 
below, was started 1 day prior implantation of the PyMT-mCh-OVA tumor. For Poly I:C 
OVA-mCherry plug experiments, a 200 µl low growth factor matrigel with 20 µg poly I:C 
and 40 µg Ovalbumin-TxRd Conjugate (ThermoFisher Scientific) was implanted into 
mammary fat pad 2/3 when 2.5x105 PyMT-B6 cells implanted into the mammary fat pad 
4/5 produced a tumor 1.0 cm in diameter, or non-primary tumor-bearing matched 
controls. Mice were analyzed 10 days after the plug was implanted. Mice for 
implantation and controls were obtained from either Charles Rivers Laboratories or The 
Jackson Laboratories. For anti-Ly6G IgGs treated arm, anti-Ly6G IgGs, as described 
below, was started one-day prior to implantation of the matrigel plug. Tumor-bearing 
mice were randomized into treatment groups, when necessary. For Ccl4-contianing plug 
iteration, a matrigel plug contained 200 µl low growth factor matrigel with 20 µg poly I:C 
and 100ng Ccl4 (PeproTech) was implanted and analyzed as described above. During 
randomization, animals were sorted by tumor size in ascending order, and then 
separated into groups in descending order. Investigator was blinded to treatment group 
during sorting. Groups were determined to have no statistical difference in average 
starting tumors size post hoc. Unless otherwise stated, animals were female C57BL/6 
mice implanted with tumors at 7-8 weeks of age and analyzed at 9-12 weeks of age. 
Flow Cytometry Analysis 
For mouse tissue, single cell suspensions were obtained prior to staining. BM was 
flushed from long bones for most analyses; for mature cDC staining, the long bone was 
crushed and digested in DMEM (Lonza) supplemented with 2 mg/mL collagenase A 
(Roche) for 25 minutes at 37 degrees Celsius with agitation. For tumor tissue analysis, 
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the mouse was subjected to perfusion with Heparin-phosphate-buffered saline (PBS) 
(Alfa Aesar, Lonza) solution prior to tissue dissection. Lymph nodes, tumors and 
matrigel plugs were minced and digested in DMEM (Lonza) supplemented with 2 
mg/mL collagenase A (Roche) and DNAse (Sigma) for 25 minutes at 37 degrees 
Celsius with agitation. All digestions were quenched with fetal bovine serum (Atlanta 
Biological). Blood was obtained by cardiac puncture and deposited in Heparin-PBS (Alfa 
Aesar, Lonza) solution. Blood was then incubated in red blood cell lysis solution 
(Biolegend) for 10 minutes. All samples were washed with 1% bovine serum albumin 
(BSA) PBS (Sigma, Lonza) staining buffer and filtered with a 40 µM mesh filter 
(FisherBrand) prior to staining. Samples were blocked on ice with rat anti-mouse 
CD16/32 for 10 minutes (except when CD16/32-PE was used). Samples were then 
resuspended in 100 µl staining buffer with extracellular fluorophore-conjugated 
antibodies and incubated on ice for 30 minutes. Samples were washed with staining 
buffer and fixed with fixation buffer (BD) for 30 minutes. When intracellular staining was 
performed, the fixation/permeabilization kit (eBioscience) was used after extracellular 
staining according to manufacturer’s instructions. For green fluorescent protein (GFP) or 
mCherry analysis, fixation was not performed and cells were analyzed immediately. 
Human BM and blood were thawed from cryopreservation into PBS (Lonza). Live/Dead 
or viability dyes were applied for 15-30 minutes at room temperature (BD). Samples 
were then processed in the same manner as the mouse samples above. Data were 
acquired on the Fortessa X20, LSRII or Fortessa system (BD). FlowJo v9 (Tree Star) 
was used for compensation and analysis. All antibodies and dilutions used are listed in 
Supplemental Tables 2.5 and 2.6.  
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Microarray and RT-qPCR Analysis 
Total RNA was isolated from GMP, MDP and CDP (as defined in gating strategies) from 
the BM of end stage PyMT-B6 tumor-bearing mice and tumor-free controls. Lineage 
depletion was performed using a Mouse Lineage Depletion Kit (Miltenyi Biotech) 
according to the manufacturer’s instructions. Cells were processed and stained as 
described above and sorted on the ARIAII system (BD). RNA was isolated using the 
E.N.Z.A. Total RNA Kit (OMEGA) according to the manufacturer’s instructions. 
Microarrays were performed on MDP and CDP samples by the Genome Technology 
Access Center (GTAC) at Washington University and data has been deposited in 
NCBI’s Gene Expression Omnibus with accession number GSE99467. Microarray data 
was analyzed using DAVID Bioinformatics Resource to develop a list of GO 
Terms120,121. Differential gene list was generated and cluster analysis was performed 
using genes with detected fold changes >1.5, p<0.05 and FDR q<0.05. RNA from 
GMPs, MDPs, and CDPs was also processed into cDNA using qScript cDNA SuperMix 
(Quantabio). Target genes were assessed using quantitative real-time PCR Taqman 
primer probes set for IRF8, Cd209a, Zbtb46, Bcl11a, Spi1, SpiB, Cebpe, Gfi1, Cebpa, 
Id2, Batf3, H2-Ke6, H2-Dma, H2-Q8, TapBP, Tap2, Pml, Tbp, and Gapdh. Relative 
gene expression was determined on an ABI7900HT quantitative PCR machine (ABI 
Biosystems) using Taqman Gene Expression Master Mix (Applied Biosystems). The 
threshold cycle method was used to determine fold change gene expression normalized 
to Gapdh and tbp. For in vitro gene expression assays, MPs, MDPs and CDPs were 
sorted as described above. Cells were cultured in Rosewell Park Memorial Institute 
(RPMI) 1640 medium (Lonza) supplemented with 10% fetal bovine serum (Atlanta 
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Biological) β-mercaptoethanol (Gibco), non-essential amino acids (Life Technologies) 
and L-glutamine (Life Technologies) in the presence of 100 ng/mL recombinant Flt3L 
and/or 100 ng/mL recombinant GCSF (PeproTech) for 24 h. Gene expression for Irf8 
was assessed by RT-qPCR protocol described above.  
Immunohistochemistry (IHC) and In Situ Hybridization (ISH) 
Human PDAC and breast cancer TMA samples were stained using anti-GCSF IgGs 
(ab9691, abcam) diluted 1:25 in blocking buffer (5% goat serum, 2.5% BSA in 1X PBS) 
on Bond Rxm autostainer. Antigen retrieval was performed using citrate-based Epitope 
Retrieval Solution (AR9961, Leica Biosystems), and immunostaining was visualized 
using 3,3′-diaminobenzidine (DAB) by Bond Polymer Refine Detection Kit (DS9800, 
Leica Biosystems) using manufacturer’s recommendations. Human PDAC and breast 
cancer TMA stained slides were scanned at 10X magnification on Zeiss Axio Scan Z1 
Brightfield/Fluorescence Slide Scanner, visualized and graded based on staining 
intensity. ISH was performed on mouse tumor tissues isolated from end stage PyMT-B6 
and KPC mice and age match normal mammary glands and pancreas. Tissues were 
fixed in 10% formalin o/n at 4°C and embedded in paraffin. 6µM sections were taken, 
dried overnight, and stained with ISH probe specific for CSF3 gene (Cat. No. 400918, 
ACD) using the RNAscope 2.5 LS Duplex Assay (Cat. No. 32240, ACD) using 
manufacturer’s recommendations for Leica Bond Rxm. For all quantifications, whole 
tissue slide scans were obtained at 10X or 20X magnification on Zeiss Axio Scan Z1 
Brightfield/Fluorescence Slide Scanner. Additional 20X brightfield images were taken on 
the Nikon Eclipse 80i Epifluorescence microscope (Nikon. Whole tissue slide scans at 
20X magnification were analyzed with HALO software (Indica Labs) using the 
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Chromogenic RNA ISH Module. This allowed for thresholding and detection of positive 
probe staining on a single cell basis, to quantify average number of probe copies per 
cell. 
In Vitro Dendritic Cell Differentiation 
BM cells were isolated, lineage depleted and stained as described above. CD45.2+ MPs 
(Lin-cKit+ScaI-), MDPs or CDPs were isolated from whole BM of tumor-bearing or tumor-
free mice by cell sorting on the ARIAII system (BD). A total of 2,500 sorted progenitors 
were plated on 1.125x106 CD45.1+ BM cell feeder culture in Rosewell Park Memorial 
Institute (RPMI) 1640 medium (Lonza) supplemented with 10% fetal bovine serum 
(Atlanta Biological) β-mercaptoethanol (Gibco), non-essential amino acids (Life 
Technologies) and L-glutamine (Life Technologies) in the presence of 100 ng/mL 
recombinant Flt3L and/or 100 ng/mL recombinant GCSF (PeproTech) in 24-well plates. 
The medium was replaced after 3 days and cultures were analyzed after 5 days. To lift 
cells, 0.05% Trypsin (HyClone) was used. Cells were stained and analyzed as 
described for flow cytometry, identifying the progeny of isolated progenitors by CD45.2 
positivity. For GCSF priming experiment, progenitors were treated with 100ng/mL GCSF 
or media alone for 24 hours prior to plating in differentiation assay described above.  
IRF8 Overexpression In Vitro 
Retroviral vectors, MSCV Irf8 T2a Thy1.1 or MSCV empty vector T2a Thy1.1 control, 
were obtained from Drs. Theresa and Kenneth Murphy (Washington University in Saint 
Louis, St. Louis, MO). Vectors were transfected into Phoenix-E cells using Trans-IT LT-
1 (Mirus) according to manufacturer’s instructions. Virus was collected at 48 hours after 
transfection and concentrated by spin at 25,000 rpms for 2 hours. CD45.2+Lin-cKit+ScaI-
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MPs were sorted at previously described and infected with concentrated virus in 8µg/ml 
polybrene by spin infection at 1800 rpms for 45 minutes. Infection allowed to proceed 
overnight. Cells were then plated into dendritic cell differentiation assay described 
above. Cells were analyzed at 3 day. Cells were maintained in 100ng/mL Flt3L and/or 
100ng/mL GCSF through infection and differentiation assay. 
In Vivo Differentiation 
BM CD45.1+Lin-cKit+ScaI- MPs were isolated as described above and transferred into 
sub-lethally irradiated 1.0 cm PyMT-B6 tumor-bearing mice and tumor-free controls by 
retro-orbital injection. After two weeks, CD45.1+ populations were analyzed by flow 
cytometry as described above.  
MDP/CDP Adoptive Transfer 
BM MDP and CDPs were isolated as described above from the tumor-free mice and 
mice bearing end stage orthotopic PyMT-B6 tumors. 26,000 cells were adoptively 
transferred into each BATF3-/- mouse by retro-orbital injection. PyMT-mCh-OVA was 
implanted as described above 3 days after adoptive transfer.  
Cytokine Analysis 
Blood serum was isolated from end stage PyMT-B6 tumor-bearing mice and tumor-free 
controls. Blood was collected by cardiac puncture and allowed to clot for 30 minutes at 
room temperature. Clotted blood was separated by spinning at 1000 x g for 15 minutes. 
Serum cytokines were measured by Milliplex Multiplex Assay (EMD Millipore) according 
to the manufacturer’s instructions. Assays were analyzed on the Luminex 100 (Luminex 
Corp.). Serum Flt3L was measured by Mouse Flt-3 Ligand DuoSet ELISA  (R&D 
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Systems) according to the manufacturer’s instructions. Serum GCSF was measured by 
Mouse GCSF DuoSet ELISA  (R&D Systems) according to the manufacturer’s 
instructions. Human patient serum was analyzed for GCSF using a Human G-CSF 
ELISA Kit (abcam) according to the manufacturer’s instructions. 
In Vivo Cytokine, Antibody and Drug Treatment 
Mice were subcutaneously injected with 2 µg recombinant GCSF (PeproTech) in 100 µl 
PBS every day for 10 days. Mice bearing 1.0-cm diameter PyMT-B6 tumors were 
treated with 30 µg Flt3L (Celldex) daily for 9 days by intraperitoneal injection. Mice 
bearing 1.0 cm diameter PyMT-B6 tumors were treated with 50 µg anti-GCSF IgGs 
(clone 67604, R&D Systems), 500 µg anti-IL6 IgGs (clone MP5-20F3, BioXCell) or 
matched isotype control three times per week by intraperitoneal injection for two weeks. 
Mice were treated with anti-Ly6G IgGs (clone 1A8, BioXCell) or matched isotype 
control, first dose 400 µg, 100µg for subsequent doses, three times per week beginning 
at time point indicated in the experiment. Mice were treated with 200 µg anti-PD1 IgGs 
(clone RMP1-14, BioXCell) every 3 days by intraperitoneal injection. Mice were treated 
with 50 µg poly I:C every 5 days by intratumoral injection, according to time points 
indicated in the experiment.  
Statistical Analysis 
GraphPad Prism Version 5 (GraphPad Software Inc.) was used for statistical analyses. 
The sample size was determined for all human and mouse analysis and in vivo 
experiments using experimental data from other studies to estimate appropriate 
numbers of samples and mice to achieve >85% confidence for a two-fold change in any 
given parameter at the p<0.05 significance level. The number of animals and in vitro 
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replicates is specified in the figure legends. Variance was analyzed using an F-test. 
Parametric data were compared using an unpaired t test. Non-parametric data were 
compared using a Mann-Whitney U-test.  p<0.05 were considered statistically 
significant. Data sets were tested for outliers using Grubbs’ test (extreme studentized 
deviate method). For tumor burden studies, two-way ANOVA was used to compare 
groups and p<0.05 was considered statistically significant. Spearman’s correlation was 
used to compare human data points. For spearman’s correlations, correlation co-
efficient (r2) and p-values are reported in the figure. Log rank (Mantel-cox) tests were 
used to assess differences in survival and p-values are indicated in the figure.  *p<0.05; 
**p< 0.01; ***p<0.001; n.s. denotes not significant. All data were presented as mean +/- 
s.e.m or as box plots.  
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2.5 Figures 
 
Figure 2.1. 
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Figure 2.1. Human breast and pancreatic cancer reduce dendritic cell progenitors 
and CD141+ cDC1s 
(a) Representative flow cytometry gating strategy for human BM pre-DCs, CD141+ 
cDC1s and CD1c+ cDC2s, including representative final plots from a BC patient and 
from a healthy control. (b) Frequency of BM MDPs, CDPs, pre-DCs, CD141+ cDC1s, 
CD1c+ cDC2s, and immature granulocytes (CD11b+CD33HighCD14-CD15+) in baseline 
BC and PDAC patients relative to healthy controls. Data from BC cohort 1 and PDAC 
cohort 1. Healthy controls n=12; BC n=10; PDAC n=19. (c) Frequency of circulating 
blood pre-DCs and immature granulocytes in baseline BC and PDAC patients relative to 
healthy controls. Data are from BC cohort 1 and PDAC cohort 1. Healthy controls n=12; 
BC n=10; PDAC n=17. (d) Frequency of BM CD141+ cDC1s and granulocytes 
(CD45+CD11b+CSF1R-CD15+CD14-), and the ratio of cDC1s/granulocytes in BC 
patients prior to treatment or surgical intervention comparing those who achieved 
pathological complete response relative to patients who did not achieve pathological 
complete response in BC cohort 2; n=18. Additional cohorts illustrated in Supplemental 
Figure 1. Error bars represent mean +/- s.e.m. or box plot; *p<0.05, **p<0.01, 
***p<0.001 by unpaired two-sided Student’s t test. 
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Supplementary Figure 1 
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Supplementary Figure 2.1.  
(a) Representative gating strategy for human BM MDPs and CDPs. (b) Representative 
gating strategy for human blood pre-DCs. (c) Frequency of BM pre-DCs, CD141+ 
cDC1s, and CD1c+ cDC2s in baseline breast cancer patients relative to healthy 
controls. Data are from breast cancer cohorts 1 and 2; healthy controls, n=12; breast 
cancer cohort 1, n=10; breast cancer cohort 2, n=21. (d) Frequency of blood pre-DCs in 
baseline pancreatic cancer patients relative to healthy controls. Data are from 
pancreatic cancer cohorts 1 and 2. (e) Frequency of BM CD1c+ cDC2s in breast cancer 
patients achieving pathological complete response relative to patients who did not 
achieve pathological complete response in breast cancer cohort 2; n=18. Box plot; error 
bars represent mean +/- s.e.m.; *p<0.05, **p<0.01, ***p<0.001 by unpaired two-sided 
Student’s t test 
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Figure 2.2. 
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Figure 2.2. Primary mammary and pancreatic tumors systemically decrease 
cDC1s  
(a) Representative flow cytometry gating strategy for mouse BM pre-DCs and cDC1s. 
(b) Number of BM MDPs, CDPs, pre-DCs, immature granulocytes, granulocytes, CD24+ 
cDC1s, and Sirpα+ cDC2 from mice bearing end-stage orthotopic PyMT-B6 mammary 
tumors relative to tumor-free controls; n=6/group. Data are representative of three 
independent experiments. (c) Number of BM pre-DCs, CD24+ cDC1, and Sirpα+ cDC2 
in end-stage genetic mouse models of BC (MMTV-PyMT) and PDAC (KPC) relative to 
tumor-free controls; tumor-free MMTV-PyMT controls n=6; MMTV-PyMT, n=6; tumor-
free KPC controls, n=7; KPC, n=8. (d) Alternative representative gating strategy using 
Zbtb46-GFP mice continued from Fig. 2a for committed pre-cDC1s, including 
representative plots from tumor-free and PyMT-B6 tumor-bearing mice. Number of 
cDC1 committed pre-DCs (pre-cDC1) in Zbtb46-GFP+ mice bearing end-stage 
orthotopic PyMT-B6 mammary tumors relative to tumor-free Zbtb46-GFP+ controls; 
n=6/group. Data are representative of two independent experiments. (e) Representative 
flow cytometry gating strategy for mouse blood pre-DCs. (f) Number of blood pre-DCs 
and granulocytes from mice bearing end-stage orthotopic PyMT-B6 mammary tumors 
relative to tumor-free controls; n=6/group. Data are representative of three independent 
experiments. (g) Number of blood pre-DCs in end-stage genetic mouse models of BC 
(MMTV-PyMT) and PDAC (KPC) relative to tumor-free controls, n=7/group. (h) Number 
of uninvolved lymph node (LN) CD103+ cDC1s from mice bearing end-stage orthotopic 
PyMT-B6 mammary tumors relative to tumor-free controls; n=6/group. Data are 
representative of two independent experiments. (i) Mice with 1.0-cm diameter orthotopic 
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PyMT-B6 tumors and tumor-free controls, were implanted with matrigel plugs containing 
poly I:C-mCherry/OVA peptides in the upper mammary fat pad. Number of CD103+ 
cDC1s in the plug and draining lymph node (LN) and OVA-specific CD8+ T cells 
(CD3+CD8+Dextamer+) in the plug 10 days after implant; n=6/group. Data are 
representative of two independent experiments. End-stage for each model is defined in 
the online methods. Error bars represent mean +/- s.e.m.; *p<0.05, **p<0.01, 
***p<0.001 by unpaired two-sided Student’s t test. 
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Supplementary Figure 2.2. 
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Supplementary Figure 2.2.  
Representative gating strategy for (a) mouse BM MDPs, CDPs, immature granulocytes, 
and granulocytes; (b) mouse blood granulocytes; (c) mouse lymph node CD103+ 
cDC1s; (d) mouse tumor and matrigel plug CD103+ cDC1s and CD11b+ cDC2s.  
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Supplementary Figure 2.3. 
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Supplementary Figure 2.3.  
Number of BM MDPs, CDPs, immature granulocytes, and granulocytes from end-stage 
genetic mouse models of (a) breast cancer (MMTV-PyMT) and (b) pancreatic cancer 
(KPC) relative tumor-free controls; tumor-free MMTV-PyMT controls, n=6; MMTV-PyMT, 
n=6; tumor-free KPC controls, n=7; KPC, n=8. (c) Number of BM pre-DCs, CD24+ 
cDC1s, and Sirpα+ cDC2s in early (1-month-old) and late (end-stage, 1.5-month-old) 
accelerated genetic mouse model of pancreatic cancer (KPPC) relative to tumor-free 
controls; n=5/group. (d) Number of BM CD24+ cDC1s and Sirpα+ cDC2s and blood pre-
DCs and granulocytes in mice with end-stage orthotopic Pan02 pancreatic tumors 
relative to tumor-free controls; n=6/group. Data are representative of two independent 
experiments. (e) Number of BM pre-DCs, CD24+ cDC1s, and Sirpα+ cDC2s, and blood 
frequency of pre-DCs in mice with end-stage orthotopic 4T1-FL-GFP mammary tumors 
relative to tumor-free controls; n=6/group. (f) Number of BM pre-DCs, CD24+ cDC1s, 
and Sirpα+ cDC2s in mice with end-stage orthotopic KP 1.0 pancreatic tumors relative to 
tumor-free controls; n=6/group. (g) Number of BM and blood plasmacytoid DCs in mice 
with end-stage orthotopic PyMT-B6 tumors. (h) Mice with 1.0-cm diameter orthotopic 
PyMT-B6 tumors and tumor-free controls were implanted with matrigel plugs containing 
poly I:C and Ccl4 in the upper mammary fat pad. Number of CD103+ cDC1s in the plug 
10 days after implant; n=6/group. (i) Ccr5 expression in blood pre-DCs in mice with end-
stage orthotopic PyMT-B6 tumors. End-stage for each model is defined in the online 
methods. Error bars represent mean +/- s.e.m.; *p<0.05, **p<0.01, ***p<0.001 by 
unpaired two-sided Student’s t test. 
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Figure 2.3.  
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Figure 2.3. Tumor burden alters the fate of myeloid progenitors  
(a) CD45.1+Lin-Sca1-cKit+ MPs were transferred into mice bearing 1.0-cm diameter 
orthotopic PyMT-B6 tumors or tumor-free controls. BM was analyzed for CD45.1+ 
populations after 2 weeks. BM MDPs, CDPs, pre-DCs, CD24+ cDC1, and granulocytes, 
and blood granulocytes displayed as frequency of CD45.1; n=5/group. (b) CD45.2+Lin-
Sca1-cKit+ MPs, CD45.2+ MDPs, and CD45.2+ CDPs were isolated from end-stage 
orthotopic PyMT-B6 tumor-bearing or tumor-free donors. Progenitors were cultured on 
CD45.1+ BM feeder culture for 5 days in the presence of 100 ng/ml Flt3L. Final cultures 
were analyzed for cDC1 (Live CD45.2+CD45.1-MHCII+CD11c+Sirpα-CD24+). End-stage 
is defined in the online methods. Data are representative of three independent 
experiments consisting of three wells per condition. GMPs, MDPs, and CDPs were 
sorted from mice bearing end-stage orthotopic PyMT-B6 mammary tumors and tumor-
free controls. (c) GMPs, MDPs, and CDPs were analyzed by RT-qPCR. (d) MDPs and 
CDPs were analyzed by microarray. Cluster analysis was performed with a differential 
genes list generated from gene with 1.5-fold at p<0.05 and FDR q<0.05 in MDP or CDP 
comparison from PyMT-B6 tumor-bearing to tumor-free. Four samples, each consisting 
of two mice were analyzed per group. (e) MDPs and CDPs were isolated from PyMT-B6 
tumor-bearing mice or tumor-free controls. Progenitors were adoptively transferred into 
BATF3-/- mice. PyMT-mCh-OVA was implanted after 3 days into wild-type mice, BATF3-
/- mice without adoptive transfer, and BATF3-/- mice with adoptive transfer from tumor-
free or tumor-bearing mice. Tumor growth was monitored. Error bars represent mean 
+/- s.e.m.; *p<0.05, **p<0.01, ***p<0.001 by unpaired two-sided Student’s t test or two-
way ANOVA. 
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Supplementary Figure 2.4 
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Supplementary Figure 2.4.  
(a) CD45.1+Lin-Sca1-cKit+ MPs were transferred into orthotopic PyMT-B6 mammary 
tumor-bearing mice or tumor-free controls. Frequency of BM inflammatory monocytes 
and resident monocytes; blood inflammatory monocytes and resident monocytes; and 
spleen CD8α+ cDC1, inflammatory monocytes and resident monocytes, as frequency of 
CD45.1; n=5/group. (b) Representative plots of Ly6G and Ly6C expression in sorted 
MPs, MDPs and CDPs after 5 days of culture with GCSF. (c) CD45.2+Lin-Sca1-cKit+ 
MPs, CD45.2+ MDPs, and CD45.2+ CDPs were isolated from end-stage orthotopic 
PyMT-B6 tumor-bearing or tumor-free donors. Progenitors were cultured on CD45.1+ 
BM feeder culture for 5 days in the presence of 100 ng/ml Flt3L. Final cultures were 
analyzed for granulocytes (Live CD45.2+CD45.1-CD11b+Ly6G+). Data are 
representative of three independent experiments consisting of three wells per condition. 
End-stage is defined in the online methods. Error bars represent mean +/- s.e.m.; 
*p<0.05, **p<0.01, ***p<0.001 by unpaired two-sided Student’s t test. 
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Figure 2.4.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. GCSF disrupts cDC1 differentiation
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Figure 2.4. GCSF disrupts cDC1 differentiation  
(a) Blood and BM serum cytokines in orthotopic PyMT-B6 end-stage tumor-bearing 
mice relative to tumor-free controls; tumor-free, n=6; PyMT-B6, n=7. (b) GCSF in 
human BC patient blood serum relative to healthy controls; healthy controls, n=30; BC, 
n=42. (c). Number of BM pre-DCs, CD24+ cDC1s, and immature granulocytes; numbers 
of blood pre-DCs and granulocytes, and tumor CD8+ T cells (CD45+CD3+CD8+) in 
tumor-free mice, orthotopic PyMT-B6 tumor-bearing end-stage mice, and orthotopic 
PyMT-B6 tumor-bearing end-stage mice treated for 2 weeks with 50 µg anti-GCSF IgGs 
3x/week; n=5-7/group. Data are representative of two independent experiments. (d) 
Number of BM MDPs, CDPs, pre-DCs, CD24+ cDC1s, and immature granulocytes, and 
number of blood pre-DCs and granulocytes in C57BL/6 mice treated with 2 µg GCSF for 
10 days; n=6/group. Data are representative of two independent experiments. (e) 
CD45.2+Lin-Sca1-cKit+ MPs, MDPs, and CDPs isolated from tumor-free mice were 
cultured on CD45.1+ BM feeder culture in the presence of 100 ng/ml Flt3L, 100 ng/ml 
GCSF, or 100 ng/ml Flt3L and 100 ng/ml GCSF for 5 days. Final cultures were analyzed 
for cDC1s (Live CD45.2+CD45.1-MHCII+CD11c+Sirpα-CD24+) and granulocytes (Live 
CD45.2+CD45.1-CD11b+Ly6G+). Data are representative of three independent 
experiments consisting of three wells per condition. (f) Experiment similar to that in Fig 
4d, but CD45.2+ cells were pre-treated with 100 ng/ml GCSF or media alone for 24 h 
prior to plating on CD45.1+ BM feeder layer. Data are representative of two independent 
experiments consisting of three wells per condition. End-stage for each model is defined 
in the online methods. Error bars represent mean +/- s.e.m or box plot. *p<0.05, 
**p<0.01, ***p<0.001 by unpaired two-sided Student’s t test. 
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Figure 2.5.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Tumor-derived GCSF inhibits cDC1 development
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Figure 2.5. Tumor-derived GCSF inhibits cDC1 development  
(a) ISH for Csf3 on end-stage PyMT-B6 and KPC tumor tissue and tumor-free 
mammary or pancreas tissue; n=3 per group. (b) Human patient BC and PDAC tumor 
tissue stained for GCSF. BC graded for low, medium, and high staining per tumor cell; 
BC, n=106; PDAC, n=5. (c) Number of BM pre-DCs, CD24+ cDC1s, and immature 
granulocytes and blood pre-DCs from mice bearing end-stage orthotopic PyMT-B6 or 
PyMT-B6 GCSFKO mammary tumors relative to tumor-free controls, n=6/group. End-
stage for each model is defined in the online methods. Error bars represent mean +/- 
s.e.m.; *p<0.05, **p<0.01, ***p<0.001 by unpaired two-sided Student’s t test. 
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Supplementary Figure 2.5.  
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Supplementary Figure 2.5.  
(a) Tumor-free, orthotopic PyMT-B6 tumor-bearing end-stage mice and orthotopic 
PyMT-B6 tumor-bearing end-stage mice treated for 2 weeks with 500 µg anti-IL6 IgGs 
3x/week were analyzed. Numbers of BM pre-DCs, CD24+ cDC1s, immature 
granulocytes, and inflammatory monocytes (CD45+CD11b+CD115+Ly6C+Ly6G-); 
n=6/groups. (b) GCSF serum concentration in mice treated with 2 µg GCSF for 5 days 
and mice bearing end-stage PyMT-B6 tumors. (c) RT-qPCR analysis of GMPs, MDPs, 
and CDPs sorted from mice bearing end-stage orthotopic PyMT-B6 mammary tumors 
and tumor-free controls, four samples consisting of two mice each were analyzed per 
group. (d) CD45.2+ Lin-Sca1-cKit+ MPs, MDPs and CDPs were cultured on CD45.1+ BM 
feeder culture in the presence of indicated GCSF and Flt3L concentration for 5 days. 
Final cultures were analyzed for cDC1s (Live CD45.2+CD45.1-MHCII+CD11c+Sirpα-
CD24+) and granulocytes (Live CD45.2+CD45.1-CD11b+Ly6G+). Data are representative 
of three independent experiments consisting of three wells per condition. (e) Relative 
IRF8 expression in BM MDPs, CDPs and pre-DCs from mice bearing end stage 
orthotopic PyMT-B6 or PyMT-B6 GCSFKO clone 1 mammary tumors relative to tumor-
free controls, n=6/group. Number of BM pre-DCs, CD24+ cDC1s and immature 
granulocytes and blood pre-DCs from mice bearing end stage PyMT-B6 GCSFKO clone 
2 mammary tumors relative to tumor-free controls, n=6/group. End-stage is defined in 
the online methods. Error bars represent mean +/- s.e.m.; *p<0.05, **p<0.01, 
***p<0.001 by unpaired two-sided Student’s t test. 
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 Figure 2.6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fi r  6. IRF8 expression is reduced during breast and pancreatic cancer
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Figure 2.6. IRF8 expression is reduced during breast and pancreatic cancer  
(a) IRF8 measured in BM MDPs, CDPs, and pre-DCs of end-stage orthotopic PyMT-B6 
tumor-bearing mice and tumor-free controls; n=7/group. Data are representative of three 
independent experiments. (b) RT-qPCR analysis of GMPs, MDPs, and CDPs sorted 
from mice bearing end-stage orthotopic PyMT-B6 mammary tumors and tumor-free 
controls, four samples consisting of two mice each were analyzed per group. (c) pStat3 
measured in BM MDPs, CDPs, and pre-DCs of end-stage orthotopic PyMT-B6 tumor-
bearing mice and tumor-free controls; n=6. Data are representative of two independent 
experiments. (d) IRF8 expression in total BM from BC and PDAC patients relative to 
healthy controls; n=10/group. Data are from BC cohort 1 and PDAC cohort 1. (e) 
Correlation between BM pre-DCs and BM IRF8 expression in BC and PDAC patients. 
Data are from BC cohort 1 and PDAC cohort 1; n=20. (f) IRF8 expression in blood pre-
DCs from PDAC patients relative to healthy controls; healthy controls n=10, PDAC 
n=43. Data are from PDAC cohort 2. (g) Correlation between blood pre-DCs and blood 
pre-DC IRF8 expression in PDAC patients; n=43. Data are from PDAC cohort 2. (h) 
Kaplan-Meier estimate of recurrence free survival and overall survival of patients +/- 
median blood pre-DCs IRF8 expression. Log-rank (Mantel-Cox) p value is denoted for 
differences in recurrence free survival and overall survival. Data are from PDAC cohort 
2. Spearman’s correlation (r2, correlation coefficient). End-stage for each model is 
defined in the online methods. Error bars represent mean +/- s.e.m or box plot; *p<0.05, 
**p<0.01, ***p<0.001 by unpaired two-sided Student’s t test. 
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Supplementary Figure 2.6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 6.
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Supplementary Figure 2.6. 
(a) RT-qPCR analysis of GMPs, MDPs, and CDPs sorted from mice bearing end-stage 
orthotopic PyMT-B6 mammary tumors and tumor-free controls; four samples consisting 
of two mice each were analyzed per group. (b) Hypergeometric test of microarray from 
Fig. 3d comparing genes differentially expressed in IRF8-/- granulocyte progenitors and 
common myeloid progenitors generated in Waight et al. and Becker et al.96,98 to genes 
differentially expressed in MDPs and CDPs from mice bearing end-stage orthotopic 
PyMT-B6 mammary tumors. End-stage is defined in the online methods.  (c) MPs, 
MDPs and CDPs treated with 100ng/ml Flt3L or media alone for 24 h. Analyzed by RT-
qPCR for Irf8. Data are representative of two independent experiments consisting of 
three wells per condition. Error bars represent mean +/- s.e.m.; *p<0.05, **p<0.01, 
***p<0.001 by unpaired two-sided Student’s t test. 
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Figure 2.7. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. GCSF regulates IRF8 in dendritic cell progenitors
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Figure 2.7. GCSF regulates IRF8 in dendritic cell progenitors 
(a) IRF8 measured in BM MDPs, CDPs, and pre-DCs of tumor-free mice, orthotopic 
PyMT-B6 tumor-bearing end-stage mice, and orthotopic PyMT-B6 tumor-bearing end-
stage mice treated for 2 weeks with 50 µg anti-GCSF IgGs 3x/week; n=6/group. Data 
are representative of two independent experiments. End-stage is defined in the online 
methods. (b) MPs, MDPs, and CDPs treated with 100 ng/ml GCSF and/or 100 ng/ml 
Flt3L for 24 h.  Analyzed by RT-qPCR for Irf8 and Batf3. Data are representative of two 
independent experiments consisting of three wells per condition. (c) CD45.2+Lin-Sca1-
cKit+ MPs transduced with CD90.1 IRF8 overexpression vector or CD90.1 empty vector 
control were cultured on CD45.1+ BM feeder culture in the presence of 100 ng/ml Flt3L 
and/or 100 ng/ml GCSF for 3 days. Final cultures were analyzed for cDC1s (Live 
CD45.2+CD90.1+CD45.1-MHCII+CD11c+Sirpα-CD24+). Data are representative of three 
independent experiments consisting of three wells per condition. Error bars represent 
mean +/- s.e.m or box plot; *p<0.05, **p<0.01, ***p<0.001 by unpaired two-sided 
Student’s t test.  
 
 
 
 
 
 
 
 
76 
Figure 2.8.  
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Figure 8. IRF8 and cDC1s are necessary for anti-tumor CD8+ T cell responses
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Figure 2.8. IRF8 and cDC1s are necessary for anti-tumor CD8+ T cell responses 
(a) Mice with 1.0-cm diameter orthotopic PyMT-B6 tumors and tumor-free controls were 
implanted with PyMT-B6-mCh-OVA cells in the upper mammary fat pad. After 7 days, 
the secondary tumor and its draining lymph node were analyzed for frequency of 
CD103+ cDC1s and OVA-specific CD8+ T cells. OVA-specific T cell analysis was also 
performed in age-matched IRF8-/- and Batf3-/- mice; n=5 mice/group. Experimental 
replicates are displayed. (b) Tumor volume over time in Batf3-/-, IRF8-/-, and wild-type 
controls implanted with orthotopic PyMT-B6-mCh-OVA tumors; wild-type, n=10; BATF3-
/-, n=7; IRF8-/- n=4. Data are representatives of two individual experiments. (c) Tumor 
volume over time in IRF8-/-, IRF8-/- treated with anti-Ly6G IgGs starting one day prior to 
implant and wild-type controls implanted with orthotopic PyMT-B6-mCh-OVA tumors; 
wild-type, n=6; IRF8-/-, n=3; IRF8-/- treated with anti-Ly6G IgGs, n=3. Error bars 
represent mean +/- s.e.m.; *p<0.05, **p<0.01, ***p<0.001 by unpaired two-sided 
Student’s t test or two-way ANOVA.  
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Figure 2.9.  
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Figure 9. GCSF neutralization synergizes with Flt3L in vivo to promote cDC1s numbers and function
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Figure 2.9. GCSF neutralization synergizes with Flt3L in vivo to promote cDC1s 
numbers and function 
Tumor-free mice or orthotopic PyMT-B6 tumor-bearing end-stage mice treated with 50 
µg anti-GCSF IgGs 3x/week for 2 weeks and/or 30 µg Flt3L daily for 9 days. End-stage 
is defined in the online methods. (a) Number of BM pre-DCs, CD24+ cDC1s, and Sirpα+ 
cDC2s. (b) Number of blood pre-DCs and granulocytes. (c) IRF8 measured in BM 
MDPs, CDPs, and pre-DCs. (d) Number of tumor CD103+ cDC1s, CD11b+ cDC2s, and 
CD8+ T cells (CD45+CD3+CD8+); n=6/group. (e) Established 1-cm+ diameter orthotopic 
PyMT-mCh-OVA mammary tumors were treated with vehicle or Flt3L (30 µg) + anti-
PD1 IgGs (200 µg) + intratumoral Poly I:C (50 µg) +/- anti-GCSF IgGs (50 ng) according 
to the displayed treatment schedule. Survival to 2.3 cm3 tumor volume. Error bars 
represent mean +/- s.e.m.; *p<0.05, **p<0.01, ***p<0.001 by unpaired two-sided 
Student’s t test. Log-rank (Mantel-Cox) p value is denoted for differences in survival.  
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Supplementary Figure 2.7. 
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Supplementary Figure 2.7.  
(a) Tumor-free, orthotopic PyMT-B6 tumor-bearing end-stage mice and orthotopic 
PyMT-B6 tumor-bearing end-stage mice treated for 2 weeks with anti-Ly6G IgGs were 
analyzed. Numbers of BM pre-DCs, CD24+ cDC1s, and granulocytes and IRF8 
expression in BM MDPs, CDPs and pre-DCs; n=6/groups. (b) Mice with 1.0-cm 
diameter orthotopic PyMT-B6 tumors, mice with 1.0cm diameter orthotopic PyMT-B6 
tumors treated with anti-Ly6G IgGs, and tumor-free controls were implanted with 
matrigel plugs containing poly I:C-mCherry/OVA peptides in the upper mammary fat 
pad. Number of CD103+ cDC1s in the plug and draining lymph node (LN) and OVA-
specific CD8+ T cells (CD3+CD8+Dextamer+) in the plug 10 days after implant; n=5-
6/group. (c) Percentage of granulocytes in the blood of tumor-free wild-type, BATF3-/-, 
and IRF8-/- mice. Number of granulocytes in the BM, blood, and tumor of wild-type, 
BATF3-/-, and IRF8-/- mice with end-stage PyMT-B6 orthotopic mammary tumors. (d) 
Number of IRF8+ pre-DCs in tumor-free mice or orthotopic PyMT-B6 tumor-bearing end-
stage mice treated for 2 weeks with 50 µg anti-GCSF IgGs 3x/week and/or 30 µg Flt3L 
daily for 9 days. (e) Tumor volume over time in established 1cm+ diameter orthotopic 
PyMT-mCh-OVA mammary tumors were treated with vehicle or Flt3L (30µg) + anti-PD1 
IgGs (200 µg) + intratumoral Poly I:C (50 µg) +/- anti-GCSF IgGs (50ng) according to 
the displayed treatment schedule. End-stage for each model is defined in the online 
methods. Error bars represent mean +/- s.e.m.; *p<0.05, **p<0.01, ***p<0.001 by 
unpaired two-sided Student’s t test or two-way ANOVA. 
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2.6 Tables 
Supplemental Table 2.1. Breast Cancer Patient Demographic Data 
 Breast Cancer 
Cohort 1 
Breast Cancer 
Cohort 2 
Age   
Median	 48 51 
Range	 37-59 30-66 
 
ER PR Her2 Count % Count % 
- - - 3 30 11 52% 
+ - - 0 0 1 5% 
- + - 1 10 1 5% 
- - + 2 20 4 19% 
+ + - 3 30 3 14% 
+ + + 1 10 1 5% 
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Supplemental Table 2.2. Gene Expression in MDP PyMT-B6 versus Tumor-Free  
Gene Fold-Change p-value Gene 
Fold-
Change p-value Gene 
Fold-
Change p-value 
Slfn14-ps -14.199222 4.84E-05 H2afy -1.757561 8.40E-05 Pabpc1l 3.164352 5.23E-04 
9430091E24
Rik -11.692082 4.99E-04 Rac3 -1.750934 2.32E-04 Srgap1 3.372656 3.59E-05 
Cd209a -11.247988 1.66E-06 Ifi203 -1.734656 1.49E-04 Mrgpra6 3.886934 2.47E-06 
Srgap3 -8.818617 2.02E-04 Bcl2 -1.705624 6.63E-04 Lcn2 4.437278 1.76E-05 
Eif2c4 -7.766489 2.31E-04 
5830469G1
9Rik -1.654133 3.77E-04 
5330421C
15Rik 4.760432 7.46E-04 
1700084E18
Rik -7.163278 2.15E-04 Mtr -1.551082 3.01E-04 Abi3 4.815156 8.93E-05 
Zfhx3 -6.163341 2.81E-04 St3gal2 -1.536023 5.69E-04 Lrg1 5.486857 2.51E-04 
Pyroxd2 -5.797396 7.81E-05 Lst1 -1.521638 7.42E-04 Vldlr 6.371575 3.59E-04 
Setdb2 -5.329231 5.67E-04 Map3k1 -1.44448 5.25E-04 Raet1c 7.024351 4.45E-04 
Olfr1537 -4.702727 5.14E-04 Dph3 1.683221 6.54E-04 Hopx 7.591526 2.79E-04 
Sema3c -4.558992 3.57E-04 Ntpcr 1.7743 7.69E-05 Retnlg 7.682535 2.00E-04 
Tom1l2 -4.454783 7.15E-04 Ptpn1 1.870916 4.03E-04 Cd300lf 7.738921 3.47E-04 
AI607873 -4.184333 6.49E-04 Gm13315 1.987459 5.27E-04 
1100001G
20Rik 8.626782 1.59E-06 
Gm7265 -3.72731 3.85E-05 Emilin2 2.000381 3.20E-05 Chi3l3 9.473319 1.92E-05 
Olfr516 -3.337054 6.92E-05 Rbm27 2.020952 3.02E-04 
2810429I0
4Rik 10.254729 1.82E-04 
Fndc9 -3.305939 3.19E-04 Ptpn1 2.088149 4.85E-04 Cttnbp2nl 10.361098 1.24E-04 
Ifi27l2a -3.240912 3.61E-04 Cartpt 2.121081 2.51E-04 
C030014L
02 11.267027 1.27E-05 
Pigm -2.992684 4.80E-04 Ctsc 2.128556 1.81E-04 Olfm1 11.26855 1.23E-04 
1700026L06
Rik -2.724752 7.12E-04 Mapk1 2.160215 2.79E-04 Prg2 13.261688 5.10E-04 
Tgtp2 -2.682215 4.28E-04 Pnp2 2.195014 1.89E-04 Spink2 15.657777 1.19E-05 
Kcng1 -2.57158 7.03E-04 Lfng 2.249454 7.68E-05 Raet1c 3.164352 5.23E-04 
4930469K13
Rik -2.553343 5.33E-04 Ntpcr 2.343655 1.87E-04 Hopx 3.372656 3.59E-05 
Dnahc8 -2.528804 6.95E-06 
1110008P1
4Rik 2.377219 1.44E-07 Retnlg 3.886934 2.47E-06 
2900005J15
Rik -2.522331 3.58E-04 Rab34 2.39526 3.26E-04 Cd300lf 4.437278 1.76E-05 
Prkd2 -2.360954 5.62E-04 Ifitm1 2.491777 3.85E-05 
1100001G
20Rik 4.760432 7.46E-04 
Tnfsf12 -2.14273 7.54E-05 Dcdc2a 2.508631 5.14E-04 Chi3l3 4.815156 8.93E-05 
Arhgap32 -2.103002 5.10E-04 Ifitm1 2.64112 3.72E-05 
2810429I0
4Rik 5.486857 2.51E-04 
B930049P2
1Rik -2.023145 2.44E-05 Gda 2.763229 5.21E-04 Cttnbp2nl 6.371575 3.59E-04 
Plin5 -2.013171 1.94E-04 Mrgpra2b 2.843982 4.88E-04 
C030014L
02 7.024351 4.45E-04 
Pdzd4 -1.927993 1.32E-04 Ctsa 2.958713 2.73E-04 Olfm1 7.591526 2.79E-04 
E330018D0
3Rik -1.925489 5.28E-04 Cyb561 3.007907 8.23E-05 Prg2 7.682535 2.00E-04 
Padi2 -1.898487 7.95E-04 Prss16 3.018601 5.52E-04 Spink2 7.738921 3.47E-04 
Smox -1.883805 3.95E-04 Pim1 3.028021 1.67E-04    
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Supplemental Table 2.3. Gene Expression in CDP PyMT-B6 versus Tumor-Free 
(top 50 up-regulated and down-regulated genes) 
Gene Fold-Change p-value Gene 
Fold-
Change p-value Gene 
Fold-
Change p-value 
Cd209a -32.729508 1.29E-04 Srgap3 -6.532035 8.55E-06 Trem3 4.8168 5.70E-06 
Klrd1 -23.532619 4.26E-05 
LOC101055
889 -6.530269 6.66E-04 Ms4a6d 4.978876 3.77E-04 
Gm6934 -23.027087 4.63E-05 Zkscan17 -6.526853 3.21E-04 Timp1 5.121362 1.57E-04 
Trp53i11 -20.385374 2.12E-04 Enah -6.519008 2.75E-04 Dmkn 5.29911 8.35E-06 
Kdm5b -15.639934 5.68E-06 Trp53i11 -6.435523 9.28E-06 Slc36a2 5.635418 2.83E-04 
Cd96 -13.871963 1.56E-04 Mmel1 -6.022855 1.88E-05 Dmkn 5.707168 4.04E-06 
2310042D
19Rik -12.788166 2.95E-06 Lrrc16a -5.876094 9.28E-05 Ccm2l 5.779491 6.84E-04 
Atp1b1 -12.443151 5.70E-05 Ngfr -5.781675 5.40E-04 Lcn2 5.947259 2.43E-06 
Nedd4 -12.340873 5.25E-09 Epb4.1l4b -5.726684 7.26E-05 Gda 6.134507 1.40E-06 
Gm15800 -12.188786 5.88E-04 Stap1 -5.606644 2.88E-04 Tgm1 6.261898 2.28E-06 
Cd209e -11.918143 1.15E-07 Rab37 -5.470566 3.33E-04 Fabp7 6.700668 7.62E-04 
Upk1b -11.861833 3.36E-06 Zeb1 -5.458445 1.99E-04 Hopx 7.01721 3.96E-04 
Erg -11.662276 2.36E-05 Lrrc16a -5.247663 1.16E-04 Cd300lf 7.111838 5.02E-04 
Snn -11.626662 3.57E-04 Tnfrsf25 -5.083078 7.33E-05 Asns 7.210553 1.86E-06 
Tspan2 -11.194533 6.23E-05 Clec1a -5.078403 9.38E-05 Cd38 7.213915 2.23E-04 
Kcnd1 -10.701696 2.34E-04 Zfp507 -4.959467 6.53E-04 Selp 7.260757 1.15E-04 
Cd209a -10.084709 2.82E-06 Cadm3 -4.901115 7.82E-04 Ccm2l 7.419001 2.59E-05 
Srgap3 -9.856634 1.27E-04 Pla2g7 3.880863 6.85E-05 Clec5a 8.024478 1.64E-04 
Spib -9.443456 5.66E-04 Il18rap 3.907484 1.26E-06 Raet1c 8.333529 2.10E-04 
Runx2 -8.458973 6.63E-06 Cd300lf 3.965554 1.27E-07 Ighv1-77 8.617922 2.80E-04 
Zbtb46 -8.273169 7.10E-04 Agpat9 3.986306 5.84E-05 F11r 9.585708 5.52E-05 
Siglech -8.271463 2.90E-04 Dio2 4.007146 2.05E-04 Socs3 11.528477 2.69E-05 
Tcf4 -8.160853 2.04E-04 Tctex1d1 4.062943 9.08E-07 BB031773 13.17378 2.62E-04 
Jakmip1 -8.107488 5.06E-04 Ifitm1 4.182093 2.45E-07 Vcan 15.487367 3.60E-04 
Soga1 -8.028317 2.99E-04 Ms4a3 4.185935 1.03E-06 Lrg1 15.686483 1.68E-06 
Bend5 -8.019112 4.01E-04 Raet1c 4.191902 7.02E-04 a 16.804754 1.84E-05 
Pid1 -7.696753 1.48E-05 Zfy1 4.264015 6.23E-04 Il22ra2 18.240837 2.23E-07 
Mmel1 -7.620589 2.41E-05 Ifitm1 4.370657 3.44E-07 Vcan 21.760314 2.24E-08 
Slfn14-ps -7.277447 7.07E-04 Vcan 4.424341 1.62E-05 
1100001G20
Rik 26.74176 9.03E-09 
Bach2 -7.08096 1.27E-04 Abi3 4.425031 1.52E-04 Il1r2 27.912414 7.08E-06 
4933427I1
8 
Rik -6.723465 1.99E-04 Irf2bpl 4.526874 6.57E-04 Clec4e 30.562592 1.50E-07 
Cd46 -6.689739 1.89E-04 Mt1 4.574931 1.38E-07 Rgcc 41.203215 4.73E-05 
E130215H
24Rik -6.532476 5.18E-07 Asb16 4.705131 2.28E-04 Crispld2 65.760643 5.57E-07 
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Supplemental Table 2.4. Enriched Biologic Process Terms 
Enriched Biologic Process Term p-Value 
Up-regulated Genes 
Innate Immunity 1.8E-04 
Secreted 2.7E-04 
Innate Immune Response 1.3E-03 
Myeloid Cell Differentiation 1.9E-03 
Positive Regulation of Cytokine Secretion 3.8E-03 
Defense Response to Bacterium 8.7E-03 
Positive Regulation of Cell Death 9.9E-03 
Cellular Response to Extracellular Stimulus 1.7E-02 
Regulation of Cell Cycle 2.0E-02 
Lipopolysaccharide-mediated Signaling Pathway 3.3E-02 
Inflammatory Response 4.1E-02 
 
Down-regulated Genes 
Transcriptional Regulation 4.2E-05 
Transcription 8.1E-05 
Covalent Chromatin Modification 7.0E-04 
Homeostasis of Number of Cells Within a Tissue 8.1E-03 
MHC Class II Protein Complex Binding 1.2E-02 
Transcription Factor Binding 1.6E-02 
Negative Regulation of Antigen Processing and Presentation of 
Peptide Antigen via MHC Class II 
2.2E-02 
Differentiation 2.8E-02 
Histone Deacetylase Binding  3.8E-02 
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Supplemental Table 2.5. Human Flow Cytometry Antibodies 
Antigen Clone Company Color Dilution 
CD3 HIT3a BD PE 1:5 
CD14 M5E2 BD PE 1:5 
CD19 HIB19 BD PE 1:5 
CD66b G10F5 BD PE 1:20 
CD45 HI30 BD BUV395 1:20 
CD141 1A4 BD BV510 1:20 
CD1c F10/21A3 BD PerCP-Cy5.5 1:20 
HLA-DR G46-6 BD PE-CF594 1:20 
CD117 104D2 BD BV605 1:20 
CD116 hGMCSFR-M1 BD BV421 1:100 
CD135 A2F10.1 BD APC 1:20 
CD45RA HI100 BD BUV737 1:20 
CD115 9-4D2-1E4 BD BB515 1:20 
Live/Dead 
Fixable Dead 
Cell Stain  
 Molecular 
Probes 
Aqua 1:1000 
Fixable Viability 
Stain 
 BD FVS780 1:1000 
 
CD45 HI30 eBioscience Alexa Fluor 700 1:20 
HLA-DR L243 Biolegend PE-Cy7 1:20 
CD14 M5E2 BD APC-Cy7 1:20 
CCR2 K036C2 Biolegend PerCP 1:20 
CSF1R 9-4D2-1E4 Biolegend PE 1:20 
CD11b ICRF44 Biolegend Alexa 488 1:20 
CD15 W6D3 Biolegend Pacific Blue 1:20 
CD16 3G8 Biolegend APC 1:20 
CD33 WM53 BD BV510 1:20 
CD1c HI30 BD PE 1:20 
CD141 1A4 BD PE 1:5 
CD335 F10/21A3 BD PE 1:5 
CD10 G46-6 BD PE 1:5 
CD303 201A Biolegend PE 1:20 
CD123 9F5 BD BV395 1:20 
CD34 581 Biolegend BV510 1:20 
IRF8 V3GYWCH eBioscience PerCP Cy5.5 1:200 
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Supplemental Table 2.6. Mouse Flow Cytometry Antibodies 
Antigen Clone Company Color Dilution 
CD45 30-F11 eBioscience APC-eFluor780 1:400 
CD45 30-F11 eBioscience PE-Cy7 1:400 
CD11b M1/70 eBioscience Alexa Fluor 700 1:400 
CD11b M1/70 eBioscience Alexa Fluor 488 1:100 
CD3e 145-2C11 eBioscience  PerCP-Cy5.5 1:200 
CD3e 145-2C11 eBioscience APC 1:200 
CD11c N418 eBioscience APC-eFluor780 1:50 
MHCII (I-A/I-E) M5/114.15.3 eBioscience eFluor450 1:400 
Ly6G 1A8 Biolegend PE 1:400 
Ly6G 1A8 Biolegend APC 1:400 
Ly6G 1A8 Biolegend FitC 1:400 
CD8 53-6.7 eBioscience FitC 1:400 
CD8 53-6.7 BD  PE-CF594 1:400 
Ly6C HK1.4 eBioscience PerCP-Cy5.5 1:400 
GR1 RB6-8C5 Biolegend Alexa Fluor 700 1:200 
CD19 eBio1D3 eBioscience APC 1:200 
CD19 eBio1D3 eBioscience Alexa Fluor 700 1:100 
F4/80 BM8 eBioscience PE-Cy5 1:400 
CD16/32 93 eBioscience Unconjugated 1:200 
Ovalbumin MHCI Dextramer  Immudex FitC 1:10 
p-Stat3 D3A7 Cell Signaling Alexa 488  
CD103 2E7 eBioscience FitC 1:50 
CD103 2E7 Biolegend BV510 1:50 
B220 RA3-6B2 Biolegend APC 1:100 
cKit (CD117) 2B8 Biolegend PE-Cy7 1:200 
Sca-1 D7 Biolegend APC-Cy7 1:100 
Flt3 (CD135) A2F10.1 BD PE-CF594 1:20 
Sirpα (CD172α) P84 Biolegend FitC 1:100 
Sirpα (CD172α) P84 Biolegend PerCP Cy5.5 1:100 
IRF8 V3GYWCH eBioscience PerCP-eFluor710 1:50 
CSF1R (CD115) AFS98 eBioscience PE 1:50 
CSF1R (CD115) AFS98 Biolegend BV605 1:200 
CD45.1 A20 eBioscience APC 1:50 
CD45.1 A20 Biolegend FitC 1:100 
CD45.2 104 Biolegend FitC 1:200 
CD45.2 104 Biolegend APC 1:200 
Streptavidin  Biolegend APC 1:200 
Lineage Cocktail  Miltenyi Biotec Biotin 1:10 
CD34 RAM34 eBioscience eFluor450 1:10 
CD16/32 93 eBioscience PE 1:200 
Ter-119 TER-119 eBioscience APC 1:200 
Siglec H eBio440c eBioscience PE-Cy7 1:100 
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Supplemental Table 2.7. Markers Used for Flow Cytometry 
Cell Type Species Tissue Markers 
All Cells Pre-Gated on Singlets and Live Cells 
GMP Human BM Lin-CD123-cKit+CD34+GMCSFR-
Flt3+CD45Ra+MCSFR- 
MDP Human BM Lin-CD123-cKit+CD34+GMCSFR-
Flt3+CD45Ra+MCSFR+ 
CDP Human BM Lin-CD123+cKit+CD34+GMCSFR+MCSFR-
CD45RA+ 
Pre-DC Human BM/Blood CD45+GMCSFR+Flt3+SSCloMCSFR-CD45RA+ 
CD141+ cDC1 Human BM CD45+CD3-CD14-CD19-CD66b-Flt3+ 
HLA-DR+CD141+CD1c- 
CD1c+ cDC2 Human BM CD45+CD3-CD14-CD19-CD66b-Flt3+ 
HLA-DR+CD141-CD1c+ 
Immature 
Granulocytes 
Human BM/Blood CD45+CD11b+CD33HiCD14-CD15+ 
Granulocyte Human Bone Marrow CD45+CD11b+CSF1R-CD15+CD14- 
MP  Mouse Bone Marrow Lin-cKit+Sca1- 
GMP Mouse Bone Marrow Lin-cKit+Sca1-CD34+CD16/32+ 
MDP Mouse Bone Marrow Lin-CD11c-MHCII-Flt3+MCSFR+cKitHi 
CDP Mouse Bone Marrow Lin-CD11c-MHCII-Flt3+MCSFR+cKitMid 
Pre-DC Mouse Bone Marrow/Blood Lin-CD11c+MHCIIlo SirpαloFlt3+ 
Pre-cDC1 Mouse Bone Marrow Lin-CD11c+Flt3+cKit+Zbtb46-GFP+ 
CD24+ cDC1 Mouse Bone Marrow Lin-Flt3+MHCII+CD11c+CD24+Sirpα- 
Sirpα+ cDC2 Mouse Bone Marrow Lin-Flt3+MHCII+CD11c+CD24-Sirpα+ 
CD103+ cDC1 Mouse Tumor/Plug CD45+Ly6C-MHCII+F4/80-
CD24+CD103+CD11b- 
CD11b+ cDC2 Mouse Tumor CD45+Ly6C-MHCII+F4/80-CD24+CD103-
CD11b+ 
CD103+ cDC1 Mouse Lymph Node B220-CD11c+MHCIIHiCD103+CD11b- 
CD8α+ cDC1 Mouse Spleen B220-CD11c+MHCII+CD8+CD11b- 
Inflammatory 
Monocytes 
Mouse Spleen CD45+CD11b+CSF1R+Ly6G-Ly6C+ 
Resident 
Monocyte 
Mouse Spleen CD45+CD11b+CSF1R+Ly6G-Ly6C- 
Immature 
Granulocytes 
Mouse Bone Marrow CD45+Lin-CD11b+MCSFR+Ly6G+ 
Granulocyte Mouse Bone Marrow CD45+Lin-CD11b+MCSFR-Ly6G+ 
Granulocyte Mouse Blood CD45+CD11b+MCSFRloLy6G+ 
(OVA-Specific) 
CD8+ T Cell  
Mouse Tumor/Plug/Lymph 
Node 
CD3+CD8+(Dextamer+) 
Plasmacytoid 
DCs 
Mouse Bone Marrow/Blood CD19-CD11b-B220+SiglecH+MHCIIMidCD11cMid 
cDC1 In Vitro  MHCII+CD11c+CD24+Sirpα- 
Granulocytes In Vitro  CD11b+Ly6G+Ly6C- 
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Chapter 3: Conclusions and Future 
Directions 
3.1 Conclusions 
Breast and pancreas cancers have had limited responses to single agent 
immunotherapy in the clinic122-125. Although this limited response might be explained in 
part by poor antigenicity, BC and PDAC are also known to expand systemic populations 
of immune-suppressive myeloid cells by increasing differentiation from myeloid 
progenitors in the BM18,43,122. Our findings suggest that tumor-induced inflammatory 
cytokines expand potentially immune-suppressive myeloid cells and simultaneously 
suppress anti-tumor cDC1 development from BM progenitors. Beyond committing to the 
granulocyte, monocyte, or cDC lineages, cDCs progenitors further commit to the cDC1 
subset before leaving the BM82,84,103,104. These findings suggest that the antigen-
presenting capacity can be defined before cells traffic into the periphery and is not 
entirely reliant on cues experienced at the tumor site. Therefore, it is important to 
understand how tumors alter BM myeloid differentiation to overcome tumor-induced 
immune surveillance. Others have shown suppression of the transcription factor IRF8 
during tumor progression expands the immature granulocyte and monocyte populations 
that are known to suppress anti-tumor immune responses96,98,110. We further 
demonstrated IRF8 downregulation during cancer reduces cDC1 development in the 
BM. This is an important finding because IRF8 expression in progenitors as early as the 
hematopoietic stem cell (HSC) primes transcriptional networks and influence lineage 
bias towards cDC and cDC1 fate79,94. Additionally, tumor-induced depletion of cDC1s 
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has a functional implication on anti-tumor immunity beyond the effect of granulocyte 
expansion. Even in the context of granulocyte depletion, reduced cDC1 differentiation 
inhibits CD8+ T cell-mediated anti-tumor responses, leading to a loss of tumor control in 
this model. Given that previous work has shown granulocyte depletion is sufficient to 
recover anti-tumor immunity in some cases46,47,126-128, we speculate there is a balance 
between the expansion of granulocytes as immune suppressors and depletion of cDC1s 
as immune stimulators that varies with tumor type, disease progression, and tumor 
models. In addition to the BM differentiation effect we have identified, reduced IRF8 
expression is also detrimental to cDC maturation following activation signals in the 
periphery because IRF8 regulates a multitude of genes involved with antigen 
presentation and expression of IL-1286,95. Together, these results suggest tumors can 
shift the net balance of immune-stimulatory and immune-suppressive BM and peripheral 
myeloid cells, via alterations in IRF8 expression through regulation of inflammatory 
cytokines like GCSF, thereby blunting anti-tumor immunity.  
Though the granulocyte-monocyte expansion in BC and PDAC has been shown 
to impede tumor immune surveillance18,43,47, it is important to consider the role of cDC1s 
in orchestrating anti-tumor CD8+ T cell responses. In these studies, the presence of 
primary tumors is sufficient to reduce the pool of pre-cDC1s and interrupt tumor-specific 
CD8+ T cell expansion. The number of CD8+ T cells in the tumor environment is 
important for response to both chemotherapy and immunotherapy19,129-132. cDC1s are 
known to regulate CD8+ T cell numbers and function in the tumor environment. To this 
end, cDC1s cross present tumor-associated antigen to reactivate CD8+ T cells within 
tumor tissues and transport antigen to the draining lymph nodes, where they stimulate 
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naïve T cells20,81,85,88-90. Intratumoral cDC1s also recruit T cells from the lymph nodes 
into the tumor by expressing CXCL9/1091,92. Furthermore, memory T cell responses are 
deficient in mice depleted of cDC1s, suggesting cDC1s are important for re-challenge, 
which could manifest at the time of metastasis or tumor recurrence in patients91. 
Together, these functions identify cDC1s as critical supporters of anti-tumor CD8+ T 
cells. Given cDC1 differentiation is interrupted in cancer, our study shows that there is 
no longer a sufficient supply of cDC1 progenitors available to populate new and 
persistent sites of inflammation, such as sites of tumor outgrowth and metastasis, and 
that this lack of cDC1s is detrimental to anti-tumor CD8+ T cell responses. 
Through their function in supporting CD8+ T cell activity, cDC1s are important for 
tumor control and response to therapies. In agreement with these data, others have 
shown that cDC1s are required for tumor control both at primary and metastatic 
sites29,30,85,112 Furthermore, cDC1s are required for responses to checkpoint 
immunotherapy, and increased cDC1 numbers improve the response to chemotherapy 
in some cancer models19,81,92,93,133. Others have shown that the number of CD141+ 
cDC1s in the tumor, especially in balance with immune-suppressive myeloid cells, is an 
important indicator of chemotherapy response and outcome in patients19,29,43,109. We 
found that increased BM CD141+ cDC1 levels, in balance with reduced BM 
granulocytes, correlate with pCR in BC patients undergoing neoadjuvant chemotherapy. 
These data suggest tumor-induced alteration in myeloid differentiation, and specifically 
cDC1 development occurring in the BM, may also impact patient response to therapy 
and predict patient outcome. Reduced IRF8 expression in the tumor as a marker of 
cDC1s is correlated with worse patient outcome19,29. Extending upon this finding, we 
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found reduced IRF8 expression in circulating pre-DCs also correlates with reduced 
overall and recurrence-free survival. Given our new understanding of how tumors 
employ IRF8 downregulation to alter myeloid differentiation, it would be interesting to 
know if IRF8 expression in the BM or blood of patients could be a novel biomarker of a 
patient’s immune status and/or response to chemotherapy and immunotherapy. 
cDC1s are rare in the tumor microenvironment, and herein we showed that 
cDC1s are limited during development in the BM by tumor-induced inflammatory 
cytokines like GCSF29,81,134. To improve adaptive immune responses against the tumor, 
especially in the context of immunotherapies and chemotherapies, we should consider 
strategies to bolster cDC1 BM development. Others have also shown that Flt3L 
treatment or CSF1 neutralization expands cDC1 numbers in the tumor and increases 
response to both chemotherapies and immunotherapies19,81. These strategies likely 
impact BM cDC1 differentiation and undermine this newly identified mechanism of 
tumor immune evasion.  Here, we neutralized GCSF to increase BM cDC1 
differentiation, which was able to further increase the efficacy of Flt3L by refining the 
IRF8-mediated cDC1 differentiation program. It is important to understand the 
interactions between cytokines and BM myeloid development so we can better 
modulate the systemic myeloid environment. These strategies could then be used in 
patients to support anti-tumor immunity and response to therapy. 
 In summary, we have shown that BC and PDAC alter the balance of immune-
stimulatory cDC1s versus immune-suppressive myeloid cells by regulating IRF8 
expression. This process leads to a favorable immune environment for tumor 
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progression. This mechanism reveals potential new biomarkers of immune response 
and targets for combination therapies (Fig. 3.1). 
3.2 Future Directions 
Can IRF8 be used as a biomarker? Can cytokine modulation be used as a 
clinically relevant therapy? 
 IRF8 regulates the granulocytes-monocyte-DC decision point, and controls the 
differentiation and phenotype of immune stimulatory DCs96-98. We show IRF8 is 
dysregulated in cancer and that this dysregulation is detectable in the blood of patients. 
It would be interesting to investigate the potential use of IRF8 expression profiling as a 
biomarker of immune status in patients as well as a predictor of response to chemo- 
and immune-therapy. To this end, it would also be important to further explore the 
relevance of this pathway in cancers beyond breast and pancreatic cancer. 
Alternatively, the systemic cytokine profiling may also be an indicator of immune status 
and could potentially be modulated for improved patient outcome. We show GCSF is 
relevant to modulation of the myeloid-DC balance in breast cancer. Other cancers may 
use GCSF or other inflammatory cytokines to modulate BM differentiation. Preliminary 
data also showed CSF1 may have some effect on cDC1 differentiation in vitro. It is 
possible that CSF1 modulates a secondary decision point, such as the cDC1 versus 
cDC2 differentiation choice, or impacts cell survival. Understanding the different ways 
that tumors can modulate differentiation in the BM will be important to therapeutic 
development and our ability to temper the systemic immune environment during cancer 
treatment. 
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What are the transcriptional networks and epigenetic alterations that are 
interrupted during cancer induced IRF8 downregulation? 
 IRF8 is a major regulator of myeloid differentiation, but more work could be done 
to understand how IRF8 and other transcription factors alter transcriptional networks 
and epigenetic signatures to influence differentiation. This is especially true in disease 
contexts such as cancer. IRF8 is known to modulate gene expression of factors that are 
involved in antigen presentation, but it is detectably upregulated as early as the HSC to 
specify DC-myeloid fate where this machinery is not yet relevant79,94. So, what is IRF8 
doing in early progenitors? Paul et al. shows different progenitor subsets with specific 
differentiation potential also have distinct chromatin landscapes79. We suspect it may be 
leading to alteration in epigenetic marks, priming progenitors to response to IRF8 itself 
as well as other transcription factors that are induced by external cytokine signaling, and 
that alterations in transcription factor expression during disease would influence this 
process.  
Is dendritic cell differentiation interrupted in aging? 
 Hematopoiesis is known to become dysfunctional with age. Specifically, HSC 
seem to be more primed to produce myeloid populations135. This leads to noticeable 
defect in immune responses that increases with age. It has been hypothesized that this 
might contribute to the development of diseases such as cancer136. Senescent cells 
contribute to this process by producing high levels of inflammatory cytokines. Recent 
work has shown that these cytokines can lead to the recruitment of immune suppressive 
granulocytes and promote tumor progression137. We wonder if these cytokines 
produced on a systemic level in the context of accumulating senescent cells with age or 
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with the induction of chronic inflammation, which is also common in aging adults, might 
lead to defect in cDC differentiation in the BM.  
What is the role of cDC1s in the bone marrow?  
 In this study, we identify changes in a BM population of cDC1s. Traditionally, pre-
DCs are though to traffic out the BM before differentiation into cDC1s or cDC2s. It is 
possible that this population is simply a more mature pre-DC population enroute to 
peripheral tissues, but it is also possible that this population function in the BM. cDC1s 
are known to regulate memory T cell responses and the BM is known to be a reservoir 
for memory T cells90,91,138. Could cDC1s be regulating memory T cell reactivation or 
homeostatic proliferation in the BM? Furthermore, cDC1s can release recruitment 
factors that pull T cells into the tumor tissue91,92. In preliminary data, we observed CD8+ 
T cells are depleted from the BM in both mice and patients during cancer, in 
coordination with the loss of cDC1s. Could cDC1s have a role in holding T cells in the 
BM, and under pathologic conditions, releasing them into the periphery? Further, cDC1s 
in the BM could regulate response to bone metastasis in ways similar to what is 
observed in peripheral tumors. 
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3.3 Figures 
Figure 3.1 
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Figure 3.1. Tumors drive reductions in cDC1 differentiation limiting anti-tumor 
immunity 
 
Under homeostatic conditions IRF8 drives a balance between granulocyte-monocyte 
differentiation and DC development. During cancer, this balance is disrupted leading to 
an expansion of granulocytes and monocytes at the expense of the DC compartment 
and in particular immune stimulatory cDC1s. This effect is driven by a reduction in IRF8 
expression in cDC progenitors driven by tumor-derived GCSF. This systemic reduction 
in cDC1 development leads to reduced anti-tumor immunity. 
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